

Annual Report 2022-23



Al-Madina Pharmaceuticals Ltd.

Core Value



Listing Photo Gallery





Al- Madina Pharmaceuticals limited is a familiar pharmaceuticals company in this sector. Al -Madina Pharmaceuticals limited started its journey for veterinary drugs in 2007 and human pharma in 2019. We are producing quality products, ensuring good services, maintaining sophisticated LAB and technology to grow up our business.

Al-Madina Pharmaceuticals limited ensures all complain for operation of factory and development of its products for increasing market share of the local pharma market significantly .

Al-Madina Pharmaceuticals limited has been designed to save the risk, maintain loss, accountability and record transaction properly. The company is maintaining a high standard of pollution free environment as per GMP regulation/WHO/government Laws.

Al-Madina Pharmaceuticals limited transitioned into a public limited company on January 6,2022. Furthermore the company was listed on Dhaka Stock Exchange (DSE) and Chittagong Stock Exchange (CSE) on may 22,2023.

At present the company existing resources and credit arrangement are deemed satisfactory to fulfill the immediate needs on its ongoing business activities.

TABLE OF CONTENTS

1. Corporate Overview	05
2. Our Vision and Mission	06
3. Letter of Transmittal	07
4. Notice of Annual General Meeting	08
5. Corporate Directory	10
6. Biography of Board of Directors, CFO and Company Secretary	11
7. Chairman Statement	14
8. Financial Highlights	15
9. Statement of Managing Director	16
10. Directors Report	18
11. Auditor's Report	48
12. Proxy Form	76

Corporate Overview:

SL No	Particulars	Status
1.	Managing Director	Md. Zakir Hossain Patwary
2.	Board of Director	Md. Zakir Hossain Patwary, Md. Billal Hossain Md. Kamrul Alam
3.	Enlisted	Dhaka Stock Exchange Ltd Chittagong Stock Exchange Ltd
4	Legal	RJSC
5	Type	Public Ltd Company
6	Authorized Capital	30,00,00,0000
7	Paid Up Capital	20,40,00,000
8	Number of Share	2,04,00,000
9	Major Products	Zolat Capsule, Thoraz 500 tablet, Raceper 20 Capsule, Claviator CV 250 Tablet, Anaprox Tablet, B3 Tablet, NS-Vet Powder, Tilvet Liquid, Set-3 Powder, Alcipro-vet Solution, Anticocci-K Powder.
10	Business Type	Manufacturing and Marketing
11	Major Sister Concerns	Smart Shoes Ltd Royal Footwear Ltd Royal Toiletries Ltd
12	Debut Trading Date	29.May 2023
13	Incorporation	Incorporated as a private limited company on July 27, 2006 then converted to public limited company on November 30, 2021



VISION

Our endeavor is to serve the society in improving quality of life by delivering state of the art products and services through maintenance of high standards of ethics creating accelerated opportunities for the employees with innovative ideas



MISSION

To establish an environment around the pharmaceuticals field through the highest level of innovative and technical support which will add value to our society and act as a driven force of our humanity.



Letter of Transmittal

Date: 16.11.2023

All the Shareholders

Bangladesh Securities and Exchange Commission

Registrar of Joint Stock Companies & Firms

Dhaka Stock Exchange Ltd.

Chittagong Stock Exchange Ltd.

Subject: Annual Report for the year ended 30 June 2023

Dear Sir(s),

We are pleased to enclose a copy of the Annual Report containing Directors' Report, Auditors' Report along with Audited Financial Statements including statement of financial position as at 30 June 2023, Statement of profit or loss and Comprehensive Income, Changes in Equity and Cash Flows for the year ended June 30, 2023.

The Proxy Form with Attendance Slip is attached at the end of the Annual Report for your use. In case of appointing a proxy, please complete the Proxy Form and submit it to our corporate office at least 48 hours before the scheduled meeting time. This will be our utmost pleasure to welcome you to the AGM of the Company.

Yours Truly



Md. Anwar Hossain

Company Secretary



Notice of Annual General Meeting

Notice is hereby given that the 17th Annual General Meeting of the Shareholders of Al-Madina Pharmaceuticals Ltd will be held on virtual media Link: <https://almadinapharma.bdvirtualagm.com> on December 14, 2023 at 11.30 a. m to transact the following business:

Ordinary Agenda:

1. To receive, consider and adopt the Directors' Auditors' Report and Audited Financial Statements for the year ended 30th June 2023.
2. To Approve Dividend for the year ended 30th June 2023 as recommended by the Board of Directors of the Company.
3. To Appoint Auditor of the Company and fixation of their remuneration for the year 2023-2024 as per ICAB Guideline.
4. To Retire/elect/re-elect the Directors of the Company.
5. To transact any other business with the permission of the chair.

Special Agenda:

1. To Consider any difference of use of proceed between actual use of QIO Fund and Budgeted Head QIO fund referred in QIO prospectus pages from 14 to 16 for using of any other factory development work or purchase of raw materials based on decision by Board of Director.

Dated: Dhaka
November 16, 2023

By order of Board of Directors



Md. Anwar Hossain
Company Secretary

Notes:

1. The record date for this AGM was 30.October 2023. The shareholders whose name will appear in the Depository/Share Register on the record date will be entitled to the dividend.
2. A member eligible to attend the Annual General Meeting is entitled to appoint a proxy to attend on his/her behalf.
3. Form or Proxy ,duly completed and stamped ,must be deposited at company's share Department at least 48 hours before the time appointed for the meeting and in default it will not be trusted as valid.
4. Members are requested to notify change of address, if any, to the company.
5. 17th AGM of the Company shall be conducted through virtual media link: <https://almadinapharma.bdvirtualagm.com>.
6. The Company will send the link of the online live portal to attend the AGM to the shareholders in due course.
7. Soft Copy of the Annual Reports of the Company will be sent to the shareholders respective e-mail addresses if any shareholder wants to see it.
8. Annual Reports will be available on the Company website: <https://almadinapharma.com>
9. The members are able to submit their question(s) and vote electronically 48 hours before commencement of the AGM and during the AGM.
10. Depository Participants (DPs)/Stock Brokers are requested to provide us with a list with particulars of margin loan accounts holding Al-MADINA shares as on the record date along with the particulars of Bank A/C of the DP/Stock Brokers and soft copy of the same at anwar.cs.ampl@gmail.com within 07 December 2023 for receiving the dividends of the margin loan holders.

11. In compliance with the Bangladesh Securities and Exchange Commission's Circular No. SEC/CMRRCD/2009-193/154 dated October 24, 2013; No benefit in cash or kind, other than in the form of cash dividend or stock dividend shall be paid to the holders of the equity securities at the 17th AGM of the Company.

12. Retirement/election/re-election of Directors of the Company will be conducted in compliance with the Companies Act, 1994, the Articles of Association of the Company and other prevailing relevant rules & regulations of the country.

Corporate Directory:

Board of Directors:

Chairman:

Md. Billal Hossain

Managing Director:

Md. Zakir Hossain Patwary

Director:

Md Kamrul Alam

Chief Financial Officer (CFO):

Mohammad Anichur Rahman

Company Secretary:

Mohammad Anwar Hossain

Head of Internal Audit:

Mr. Nazrul Islam

Executive Management Committee:

Md.Zakir Hossain Patwary,Managing Director

Md. Billal Hossain,Chairman

Md. Kamrul Alam,Director

Mohammad Anichur Rahman,CFO

Mohammad Anwar Hossain,Company Secretary

Md. Atikul Islam ,Head of Operation

Md.zahirul Islam,Head of Marketing

Md.Rafiqul Islam,G.M (Plant Operation)

A.B.M Shamsul Alam ,Manager (HR and Administration)

Statutory Auditor:

Md Anwar Hossain,FCA

Partner

Anil Salam Idris & Co

Chartered Accountants

House#57 (2nd Floor),Road #04 Block 1, Banani,

Dhaka-1213 Bangladesh.

Listing:

1. Dhaka Stock Exchange Ltd.

2. Chittagong Stock exchange Ltd.

Registered Office:

1/1,Tilargati,Kakil,Tongi-1711,Gazipur.

Corporate Office:

178-179, Tejturi Bazar Road, Farmgate, Dhaka.

Factory:

1/1,Tilargati,Kakil, Tongi-1711,Gazipur.

Main Bankers:

Islami Bank Ltd.

Shahjalal Islami Bank Ltd.

Pubali Bank Ltd.

IFIC Bank Ltd.

Al-Arafah Bank Ltd.

Dutch Bangla Bank Ltd.

Biography of Board of Directors, CFO and Company Secretary:



Md Billal Hossain
Chairman

Mr. Billal Hossain was born in a prominent Muslim family living in Laximpur. He has completed his graduation in BSc. He has over 20 years experienced in Pharmaceuticals, Footwear, Toiletries, Agro, Construction and Developer industry. He is a key player in expanding his business. He has taken decision, business planning, designing, indicating and implementing in financing, investing and operating successfully. He is well organizer, dedicated and motivated, self-starter with years of experience in the various Sectors. He has been carrying out in vast rule both in principle and agent in different products. He is a creative and resourceful community service. Also, has interest in number of Companies (AL- Madina Pharmaceuticals Ltd (Animal and Human Division), Royal Footwear Ltd

(footwear), Smart shoes Ltd (Footwear), Royal Toiletries Ltd (Diaper and Toiletries), Marigold Real Estate Ltd (Construction and Development), Marigold Associate Ltd (Construction and Development), Tulip Super agro Industries Ltd. and proprietor of 02 No. of units M/S Belal and Brother and M/S Sciencetech Corporation .

Md Zakir Hossain Patowary
Managing Director



Md Zakir Hossain Patowary was born in a prominent Muslim family living in Laximpur. He has completed his Post graduation in M.Sc. He has over 20 years experienced in Pharmaceuticals, Footwear, Toiletries, Agro, Construction and Developer industry. He is a key player in expanding his business. He has taken decision, business planning, designing, indicating and implementing in financing, investing and operating successfully. He is well organizer, dedicated and motivated, self-starter with years of experience in the various Sectors. He has been carrying out in vast rule both in principle and agent in different products. He is a creative and resourceful community service. He also has interest in number of Limited Companies (AL - Madina Pharmaceuticals Ltd (Animal and Human Division), Royal Footwear Ltd (footwear), Smart shoes Ltd (Footwear), Royal Toiletries Ltd (Diaper and Toiletries), Marigold Real Estate Ltd (Construction and Development), Marigold Associate Ltd (Construction and Development), Tulip Super agro Industries Ltd. and proprietor of 06 No. of units Al Madina pharmaceuticals, Al Madina Traders, Al Madina Printing Press, Tech Squard, Royal Shoes and Royal Motors.



Md Kamrul Alam
Director

Md Kamrul Alam was born in a prominent Muslim family living in Laximpur. He has completed his graduation in B.A. He has over 20 years experienced in Pharmaceuticals, Footwear, Construction and Developer industry. He is a key player in expanding his business. He has taken decision, business planning, designing, indicating and implementing in financing, investing and operating successfully. He is well organizer, dedicated and motivated, self-starter with years of experience in the various Sectors. He has been carrying out in vast rule both in principle and agent in different products. He is a creative and resourceful community service. He was Director of 04 No. of Limited Company (AL -Madina Pharmaceuticals Ltd (Animal and Human Division), Royal Footwear Ltd (footwear), Smart shoes Ltd (Footwear), Marigold Real Estate Ltd (Construction and Development) and proprietor of M/S Care International.

Mohammad Anichur Rahman
Chief Financial Officer

Mohammad Anichur Rahman has completed Master of Business Administration, Major in Accounting from Islami University, Kushtia in 2000. He has a lot of Experience on Accounting, Finance Audit, Tax, Vat , Costing and Operations in the company. He has good knowledge on IFRS, IAS, Tax, Vat, and Company Operation. He is playing the significant role for developing of the Company. He is also serving as a Chief Operating Officer of the Company. He has more than 23 year's professional experience in different area



Mohammad Anwar Hossain
Company Secretary



Md. Anwar Hossain has completed Master of Business Administration, Major in Accounting from Rajshahi University in 2004. Has also passed income tax practitioner examination under National Board of Revenue. He has a lot of Experience on Accounting, Finance Audit, Tax, Vat and Costing in different organization. He has a profound and wide spread knowledge on IFRS, IAS, Tax, Vat, RJSC, BSEC Rules and different law, rules and regulation. He has value added role play for the company. He has more than 20 year's professional experience in different organization.

Human Resources



Chairman Statement:



Dear Shareholders
Assalamu - Alaikum

I am very pleased to welcome all the shareholders in the 17th Annual General Meeting of Al-Madina Pharmaceuticals Limited. Before that you have received the Annual Report along with Directors Report and Audited Financial Statements for the year ended 30th June 2023.

As you know that now we are facing unfavorable global situation due to war between Russia and Ukraine. At this situation every Company has no avail raw materials as per their production and sales demand. After all we are proceeding our business through our proper planning, skill employees and proper use of our resources. The dedication of our employees will help to create the brands of our products.

Finally, on behalf of the board, I would like to congratulate and warmly thanks to all of our employees for their achievement throughout 2023. As well as thanks to our all shareholders, customers, suppliers, bankers and other stakeholders for their continual support to develop our business. We hope and believe, we will able to overcome all challenges in upcoming year.

I wish for success of the company in future.

Yours truly

A handwritten signature in black ink, appearing to be 'Md. Billal Hossain'. The signature is fluid and cursive, written over a white background.

Md. Billal Hossain
Chairman

Financial Highlights: Financial Position at a Glance:

Particulars	30 June 2023	30 June 2022	30 June 2021	30 June 2020	30 June 2019
ASSETS					
Non-Current Assets	317,176,332	333,166,382	328,029,470	40,219,534	41,994,210
Current Assets	322,700,893	214,101,090	144,709,219	126,150,719	45,393,168
TOTAL ASSETS	639,877,225	547,267,472	472,738,689	166,370,253	87,387,378
EQUITY AND LIABILITIES					
Equity attributable to the owners of the company	404,268,996	333,400,775	287,662,235	20,506,848	10,030,419
Non-Current Liabilities	15,589,991	15,257,539	16,412,304	10,343,978	12,063,115
Current Liabilities & Provisions	220,018,240	198,609,159	168,664,150	135,519,427	65,293,844
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	639,877,225	547,267,472	472,738,689	166,370,253	87,387,378
Net Asset Value Per Share with Revaluation	19.82	21.65	22.47	-	-
Net Asset Value Per Share without Revaluation	13.00	12.63	11.62	68.36	33.43

Statement of cash flows at a glance:

Particulars	2022-2023	2021-2022	2020-2021	2019-20	2018-19
A. Cash Flow from Operating Activities	(26,323,262)	(8,401,604)	44,973,738	(75,065,338)	10,855,893
B. Cash Flow from Investment Activities	(7,690,815)	(24,516,710)	(68,871,538)	(3,082,483)	(9,658,553)
C. Cash Flow from Financing Activities	59,608,466	37,541,951	22,464,836	90,953,207	(1,127,933)
D. Net cash flow for the year (A+B+C)	25,594,389	4,623,638	(1,432,964)	12,805,386	69,407
E. Opening Cash and Cash Equivalents	16,621,348	11,997,710	13,430,674	625,288	555,881
F. Closing Cash and Cash Equivalents	42,215,736	16,621,348	11,997,710	13,430,674	625,288

Revenue at a Glance:

Particulars	2022-2023	2021-2022	2021-2020	2020-2019	2019-2018
Sales Revenue	685,624,856	668,965,108	556,164,433	371,565,576	228,664,494
Gross Profit	280,726,968	270,668,403	205,339,144	111,324,630	47,629,400
Operating Profit	48,272,126	46,201,758	43,581,370	29,618,413	5,130,880
Net Profit / (Loss) for the year Before WPPF	33,756,479	33,880,603	30,773,331	14,633,151	331,906
Net Profit / (Loss) before Tax	32,149,027	32,267,241	29,307,934	13,936,334	331,906
Net Profit / (Loss) after Income Tax	25,166,171	19,738,540	23,188,337	10,476,429	(1,040,081)
Other Comprehensive Income:	-	-	138,967,050	-	-
Revaluation Reserve	-	-	143,265,000	-	-
Total Comprehensive Income	25,166,171	19,738,540	162,155,387	10,476,429	(1,040,081)
Earnings Per Share Basic	1.57	1.30	33.99	34.92	(3.47)

Statement of Managing Director:



Dear Shareholders
Assalamu -Alaikum.

With hope and gratification, I cordially welcome the shareholders in the 17th Annual General Meeting of AL-Madina Pharmaceuticals Ltd. We are going to arrange 17th Annual General Meeting through online platform for the first time. It is our pleasure to present you in this Annual General Meeting.

We have been operating our business from long time with goodwill. We have started our business with Agroveter division. After that we have added Pharma division. We have developed our business through our commitment. Now, we are facing so many challenges to operate our business. At this moment, we are not able to arrange raw materials as per our demand due to start the war between Russia and Ukraine. We hope we will be able to overcome this limitation through our proper plan and skill very soon. After all by grace of

Almighty Allah, we are pleased for report of successful year 2023. The Company is stated the financial position (summary) for the year ended June 30, 2023 in following way.

Particulars	Amount BDT
Sales Turnover	685624856
Gross profit	280726968
Operating Profit	48272126
Net Profit after Tax	25166171
Net Asset value per share with revaluation	19.82
Earnings Per share	1.57

We will start the new product line of liquid Section very soon and new other products based on market demand which will be significantly increasing our market share in upcoming years.

We are committed to maintain our product quality and given the patients smile on the face. We are constantly putting our effort to increase our market share and introduce the new products.

Finally, I encourage to all of our shareholders, bankers, customers, suppliers, our employees for their support to develop our business. I am waiting for upcoming development of the company.

Yours sincerely



Md. Zakir Hossain Patwary
Managing Director



Directors Report:

Dear Shareholders

Assalam-Alaikum

The Directors are delighted to present the annual report together with the audited financial statements of the company for the year ended 30 June 2023.

This report has been prepared according to section 184 of the companies' act 1994 and Bangladesh Securities and Exchange Commission Notification No BSEC /CMRRCD/2006-158/207/admin/80 dated 3 June 2018. The directors has presented their report on certain issues which deemed relevant and significance to ensure the compliance.

Background of the company:

Al-Madina Pharmaceuticals Limited is a private limited company duly incorporated in Bangladesh on 27 July, 2006 under Companies Act 1994, vide Certificate of Incorporation No. C-62976(467)/06\, and its commercial operations commenced on 21 October, 2007.

The address of the company are as follows:

Registered and Factory Office: 1/1, Tilargati, Kakil, Tongi-1711, Gazipur.

Corporate Head Office: 178-179, Farmgate, Tejturi Bazar Road, Road-23, Ward-39, Tejgaon, Dhaka.

Principal Activities:

The Company is engaged in the manufacturing, buying, selling, refinement, import, export or otherwise of pharmaceutical and medicinal products, and preparations, patent drugs and proprietary articles of all kinds, whether basic or derived and in all forms. Al-Madina Pharmaceuticals Limited started a journey for veterinary drugs in 2006 and human drugs in 2019. At present, it is manufacturing veterinary drugs such as antibacterial drugs, nutritional products, poultry vaccines, aqua products, daily injectable products etc. and human drugs such as anti-bacterial drugs, anti-fungal drugs, gastro-intestinal drugs, analgesic & anti-inflammatory drugs, vitamins-minerals or supplements, drugs acting on urogenital system and drugs acting on respiratory system etc.

Business Risk:

Adhering to IFRS 7: Financial Instruments, the financial statement has been formulated with consideration of credit risk, liquidity risk, and market risk.

Credit Risk: The Company operates under a credit policy that guides credit issuance. Security measures, such as obtaining blank cheques from customers and counterparties, are implemented during credit sales, minimizing credit risk exposure.

Liquidity Risk: Liquidity risk arises from financial obligations. The Company's sales team is dedicated to adhere a systematic collection plan for sales proceeds. As a result, the Company's liquidity risk is kept at a minimum.

Property, Plant and Equipment:

The Company has invested total sum of tk 41.61 Core in Property, Plant and Equipment. Movement in Property, Plant and Equipment during the year in disclosed under note 4 of the Financial Statements.

Our Strenght:



Performance of the Company:

The revenue of Al-Madina Pharmaceuticals Ltd has reached tk 68.56 Core during the year which is higher by 2.50% over the previous year's revenue of tk 66.89 Core. Operating Profit has increased by 4.32 % than the previous year. Net profit after tax has increased by 27.49% than the previous year. Earnings per Share has increased by 20.76% than the previous year. Cost of Goods Sold during the year was at tk 40.48 Core which is higher by 1.02% than the previous year. Gross Profit margin has increased by 4.66% than the previous year.

Existing Product List :**Agro vet Division:****DGDA Registered Products:**

Sl.	DAR No	Name of Product	Generic Name &v Strength	Pack Size
1	294 -04(V) -77	Tylotrat 20 Powder	Tylosin Tartrate BP 22.50 gm (Eqv. to 20.00 gm of Tylosin BP)	100gm Sachet
				500gm Container
				1 kg Container
2	294 -06(V) -77	Almolin -Vet Powder (Vet)	Amoxicillin Trihydrate BP 34.50gm (Eqv.to 30.00gm of Amoxicillin BP)	100gm Sachet
				500gm Container
				1 kg Container
3	294 -07(V) -77	Alcipro Solution (Vet)	Ciprofloxacin HCL USP 11.644 (Eqv. to 10.00 gm of Ciprofloxacin USP)	100ml Bottle
				500ml Bottle
				1 Ltr Bottle
4	294 -09(V) -77	Altetra Bolus (Vet)	Oxytetracycline HCL BP 540.00 mg (Eqv.to 500 gm of Oxytetracycline BP)	4 X 5' Bolus
5	294 -10(V) -77	Altetra Powder (Vet)	Oxytetracycline HCL BP 21.60 gm (Eqv.to20.00 gm of Oxytetracycline BP)	100gm Sachet
				500gm Container
				1 kg Container
6	294 -13(V) -77	Cocsomix plus powder	Sulfacholoropyridazine USP 10.000 mg + Trimethoprim BP 2.000gm	100gm Sachet
				20 gm Sachet
				500gm Container
				1 kg Container
7	294 -14(V) -77	Wormfree Bolus(Vet)	Albendazole USP 600.00 mg	4 X 5' Bolus
8	294 -15(V) -77	Al -Sulpha Bolus (Vet)	Sulfadiazine BP 1.666 mg + Sulfadimidine BP 1.666 mg + Sulfapyridine BP 1.666 mg	4 X 5' Bolus
9	294 -16(V) -77	Hemorex Bolus (Vet)	Cobalt Sulphate BP 50.000 mg + Ferrous Sulphate BP 100.000 mg + Thiamine Mononitrate USP 25.000 mg + Vitamin 10B12 USP 20.000 mg + Choline Bitartrate BP 9.100 mg	4 X 15' Bolus

10	294 -17(V) -77	Helmacid - Vet Poowder	Piperazine Citrate BP 100.000gm (Eqv.to36.000 gm of Piperazine BP)	500gm Container
				100gm Sachet
				20 gm Sachet
11	294 -18(V) -77	Alenro -Vet Solution	Enrofloxacin INN 10.00 gm	100ml Bottle, 500 ml, 1 ltr
12	294 -19(V) -77	Alcocci Powder (Vet)	Sulphaclozine Sodium Monohydrate INN 30.000 gm	500gm Container
				100gm Sachet
				20 gm Sachet
13	294 -20(V) -77	An -Worm Blous (Vet)	Triclabendazole INN 900.00 gm + Levamisole HCL BP 707.13 mg (Eqv.to 600 gm of Levamisole BP)	4 X 5' Bolus
14	294 -21(V) -77	Almolin Vet Bolus	Amoxicillin Trihydrate BP 575.00 mg (Eqv.to 500 mg of Amoxicillin BP)	2 X 10' Bolus
15	294 -23(V) -77	Promethazine Bolus (Vet)	Promethazine Hydrochloride BP 150.00 mg	10 X 4' Bolus
16	294 -24(V) -77	Ferum Bolus (Vet)	Antimony Potassium Tartrate USP 2000.00 mg + Ferrous Sulphate USP 2000.00 mg	4 X 5' Bolus
17	294 -25(V) -77	Amovet Bolus (Vet)	Metronidazole BP 2000.00 mg	4 X 5' Bolus
18	294 -27(V) -77	SET - 3 Powder (Vet)	Erythromycin Thiocyanate INN 18.00 gm + Sulphadiazine BP 15.000 mg + Trimethoprim BP 3.000 gm	10gm, 20gm,100gm Sachet
				500gm Container
				1 kg Container
19	294 -29(V) -77	Antifever Bolus (Vet)	Paracetamol BP 2000.00 mg	10 X 2' Bolus
20	294 -30(V) -77	Anticocci - K Powder	Sulphadimethoxine BP 2.00 gm + Sulphadimidine BP 20.00 gm + Diaverdine BP 3.00 gm + Niccotinamide BP 3.00gm +VitaminK3 USP 2.00 gm	100gm Sachet
				500gm Container
21	294 -31 (V) -77	Sulmidine Bolus (Vet)	Sulphadimidine BP 5000.00 mg	10 X 2' Bolus
22	294 -32 (V) -77	Germfree Liquid (Vet)	Povidone - Iodine USP 10.00 gm	1 Ltr Bottle
				100ml Bottle

24	294 -34 (V) -77	Alvasol Powder (Vet)	Levamisole HCl BP 35.36 gm (Eqv.to 30.00gm of Levamisole BP)	10 X 100gm
25	294 -35(V) -77	Alcipro Bolus (Vet)	Ciprofloxacin HCL USP 873.00 mg (Eqv. to 750 gm of Ciprofloxacin USP)	10 X 2' Bolus
26	294 -36 (V) -77	NS - Vet Powder	Neomycin Sulphate BP 50.00 gm	100gm Sachet
				500gm Container
				1 kg Container
				20 gm Sachet
27	294 -38(V) -77	Altetra- Vet LA Injection	Oxytetracycline Dihydrate (Sterile) BP 2.157 gm (Eqv.to 2gm Oxytetracycline)	10ml Amber Colored
				50ml.Amber Colored
28	294 -39(V) -77	Algenta - Vet Injection	Gentamycin Sulphate (Sterile) BP 1.70 gm (Eqv.to 1 gm of Gentamcin)	10ml Amber Colored glass
				100ml Amber Colored glass Vial
29	294 -40 (V) -77	Nitroworm - Vet Injection	Nitroxynil BP 3.4 gm	10ml Amber Color glass Vial
				100ml Amber Color glass Vial
30	294 -41 (V) -77	Hyvit ADE - Vet Injection	Vitamin A Palmitate BP 5,000,000 IU + Vitamin D3(Colecalciferol) BP 750,000 IU + Vitamin E Acetate BP 500 mg	10ml Amber Colored glass Vial
				100ml Amber Colored glass Vial
31	294 -42 (V) -77	Albu - Vet Injection	Buparvaquone BP 500 mg	10ml Amber Color glass Vial
				50ml, Amber Color glass Vial
32	294 -43 (V) -77	Alhista Vet Injection	Pheniramine meleate BP 227.5 mg	10ml Amber Colored glass Vial
				100ml,Amber Colored glass Vial
33	294 -44 (V) -77	Calplus - Vet Injection	Calcium Gluconate BP 2.08 gm + Magnesium Hydrophosphite BP 0.50 gm + Dextrose Monohydrate BP 2.00gm	100ml Amber Colored glass Vial
34	294 - 45 (V) -77	Fatisol - Vet Injection	Butaphosphan INN 1.0 gm + Cyanocobalamin BP 500 mcg	10ml Amber Colored glass Vial
				100ml Amber Colored glass Vial

35	294 - 046 (V) -077	Al-Doxil Powder (Vet)	Doxycycline Hydrochloride BP 11.500 gm (Eqv. to 10.00 gm of Doxycycline)	100gm Sachet
				500gm Container
				1 kg Container
				20 gm Sachet
36	294 -047(V) -077	Mexicam Bolus (Vet)	Meloxicam BP 100.00 mg	4 X 10' Bolus
37	294 -048(V) -077	T-Zuril Vet Liquid	Toltrazuril BP 2.50 gm	500ml Bottle
				1 Ltr Bottle
				100ml Bottle
38	294 -049(V) -077	Tilvet Liquid (Vet)	Tilmicosin phosphate USP 250.00 mg	500ml Bottle
				100ml Bottle
39	294 -050(V) -077	Zinc Liqid (Vet)	Zinc Sulphate Monohydrate BP 2.00gm	500ml, 100ml Bottle
40	294 -051(V) -077	Summer Cool Powder (Vet)	Acetyl Salicylic Acid BP 6.70gm + Vitamin - C USP 20.0gm	100gm,500gm sachet ,1kg container
41	294 -052(V) -077	Glue - C powder (Vet)	Ascorbic Acid BP 2.00gm + Glucose Anhydrous BP 98.00gm	100gm,500gm sachet
42	294 -053(V) -077	Hyvit ES liquid (Vet)	Vitamin E Acetate BP 10.0 gm + Sodium Selenite BP 0.05gm	100ml,500ml,1.0 Ltr Bottle
43	294 -054(V) -077	Asvit - C powder (Vet)	Ascorbic Acid BP 1000.0mg	100gm ,500gm Sachet
44	294 -055(V) -077	Thiarip Powder (Vet)	Thiamine Hydrochloride BP 6.0gm + Riboflavin Sodium - 5 Phosphate BP 1.10gm + Pyridoxine Hydrochloride BP 0.61gm	100gm ,500gm Sachet
45	294 -056(V) -077	Apitazym powder (Vet)	Ammonium Bicarbonate BP 25.0 gm + Sodium Bicarbonate BP 65.0 gm + Nuxvomica BP 7.0 gm + Ginger Powder BP 1.5 gm + Gentian Powder BP 1.5 gm	20gm , 500 gm Sachet
46	294 -057(V) -077	Hyzine + B Liquid (Vet)	Thiamine Hydrochloride BP 0.5gm + Riboflavin Sodium - 5 Phosphate BP 0.15gm + Pyridoxine Hydrochloride BP 0.8 gm + Nicotinamide BP 0.4gm + Zinc Sulphate Monohydrate BP 2.00gm	100ml ,500ml 1 Ltr Bottle
47	294 -058(V) -077	Hylte Powder (Vet)	Sodium Chloride BP 26.60gm + Sodium Bicarbonate BP 50.0gm + Potassium Chloride BP	100gm sachet , 500gm, 1 Ltr Container

48	294 -059(V) -077	Hyvit - BC Powder (Vet)	Ascorbic Acid BP 0.50gm + Riboflavin Sodium - 5 Phosphate BP + 0.40gm + Thiamine Hydrochloride BP 0.20gm + Pyrid oxine Hydrochloride BP 0.15gm + Nicotinamide BP 0.75gm + Calcium D Pantothenate BP 0.45gm + Vitamin B12 % BP 0.001gm + Folic Acid BP 0.025gm + Biotin 2 % BP 0.0015gm + Dextrose Anhydrous BP 97.53gm	100gm sachet , 500gm, 1 kg Container
49	294 -68(V) -77	AL-CTC Vet Powder	Chlortetracycline Hcl BP 20.0 gm	100gm sachet , 500gm, 1 kg Container
50	294 -69 (V) -77	LV-VET Powder	Levofloxacin Hemihydrate USP 10.25gm (Eqv. To 10.0 gm Levofloxacin)	100gm sachet , 500gm, 1 kg Container
51	294 -70(V) -77	AMPO - VET Powder	Amprolium Hydrochloride BP 20.0gm	100gm sachet , 500gm, 1 kg Container
52	294 -71(V) -77	ALCIPRO -VET Bolus	Ciprofloxacin Hydrochloride USP 1164.00mg (Eqv. to 1000.00 mg of Ciprofloxacin USP)	(10 x 2'S) Bolus
53	627 -4896(V) -18	BRONCHIPHARM (Vet)	Avian Infectious Bronchitis Virus, Live, strain H 120 Eurpharm 10 ^{3.0} EID ₅₀ -10 ^{4.5} EID ₅₀	100,500,1000,5000 Doses
54	627 -4897(V) -18	BURSIPHARM (Vet)	Infectious Bursal Disease Virus, Live (strain 2512) Eurpham min.10 ^{3.0} TCID ₅₀	100,500,1000,2000,5000 Doses
55	627 -4898(V) -18	PESTIPHARM B1 (Vet)	Newcastle Disease Virus, Live, Strain Hitchner B1 Eurpharm 10 ^{6.0} EID ₅₀ 10 ^{7.0} EID ₅₀	100,500,1000,2000,5000 Doses

DLS Category Product List:

190-19-(16)-001	Biovit -ES	Each ml Contains: Vitamin E Acetate BP 100 mg, Sodium Selenite BP 0.5 mg, Biotin BP 50µg	100ml, 500ml, 1L
190-19-(16)-002	Zinc Liquid	Each 100 ml Contains: Zinc Sulphate Monohydrate BP 2.00 gm	100ml, 500ml, 1L
190-19-(16)-003	Glu-C Vet	Each 100 gm Contains: Glucose BP 98 gm & Vitamin C BP 2 gm	100gm, 500gm, 1kg
190-19-(16)-004	Hyvit-ES	Each ml Contains: Vitamin-E Acetate BP 100 mg, Sodium Selenite BP 0.5 mg	100ml, 500ml, 1L
190-19-(16)-005	Thiarip	Each Kg Contains: Thiamine Hydrochloride BP 60.00 gm, Riboflavin Sodium-5 Phosphate BP 11.00 gm, Pyridoxine Hydrochloride BP 6.10 gm	100gm, 500gm, 1kg
190-19-(16)-006	Hyzinc+B	Each ml Contains: Zinc Sulphate Monohydrate BP 20.0 mg, Thiamine HCl BP 5.0 mg, Riboflavin Sodium-5 Phosphate BP 1.50 mg, Pyridoxine HCl BP 8.00 mg, Nicotinamide BP 4.0 mg	100ml, 500ml, 1L
190-19-(16)-007	AM Hepaton	Each Ltr. Contains: Vitamin B1 200 mg, Vitamin B2-5-phosphate 200 mg, Vitamin B6 200 mg Vitamin B12 200 mg, Pantothenol 1100 mg, Niacin 6000 mg, Folic Acid 30 mg, Betaine 4000 mg, Choline Chloride 5000 mg, L-Glycine 5000 mg, Vitamin K 65 mg, Inositol 100 mg, L-Lysine HCl 8000 mg, DL-Methionine 5000 mg L-Threonine 1000 mg, L-Tryptophan 250 mg, Sodium Propionates, Potassium Sorbate	100ml, 500ml, 1L, 25L
190-19-(16)-008	AM Aminosol	Each 1000 ml Contains: Vitamin A 15000000 IU, Vitamin D/Vitamin D3 200000 IU, Vitamin E 8000 mg, (as all-rac-alpha-tocopheryl acetate) Vitamin B1/Thiamine Mononitrate 1800 mg, Vitamin B2/Riboflavin-5-Phosphate ester monosodium salt 1300 mg, Vitamin B6/Pyridoxine Hydrochloride (3a831) 800 mg, Vitamin B12/Cyanocobalamin 12 mg, Nicotinic acid/Nicotinic acid amide(Nicotinamide) 12500 mg, Vitamin C/L-Ascorbic acid 22000 mg, Vitamin K (as Menadione Sodium Bisulfite) 1000 mg, Pantothenic acid/D-Panthenol 5000 mg, Folic acid 250 mg, Glutamic acid 150000 mg, L-lysine 80000 mg, Alanin 43000 mg, Valin 30000 mg, Aspartic acid 17000 mg, L-tryptofane 12000 mg, DL-Methionine 12500 mg, Cysteine 9000 mg, Histidine 3000 mg, Serine 5000 mg, Isoleucine 5000 mg, L-Threonine 5000 mg, Glycine 5000 mg, Proline 4000 mg, Leucine 4000 mg, Arginine 4000 mg, Tyrosine 3000 mg	100ml, 500ml, 1L 25L
190-19-(16)-009	AM Layer Premix	Each 2.5 Kg Contains: Vitamin A 12,000,000 IU, Vitamin D3 2,400,000 IU, Vitamin E 23gm Vitamin K3 4 gm, Vitamin B1 2 gm, Vitamin B2 5 gm, Vitamin B6 4 gm, Nicotinic Acid 30 gm, Vitamin B12 10 mg, Pantothenic Acid 10 gm, Folic Acid 500 mg, Biotin 50 mg, Cobalt 250	25kg, 50kg

		mg, Iron 6 gm, Copper 24 gm, Iodine 600 mg, Manganese 50 gm, Zinc 40 gm, Selenium 120 mg, DL-Methionine 50 mg, L-Lysine 30 gm, Carrier (Calcium Carbonate) q.s. to 2.5 kg	
190-19-(16)-010	AM Broiler Premix	Each 2.5 Kg Contains: Vitamin A 12,500,000 IU, Vitamin D3 2,500,000 IU, Vitamin E 30 gm, Vitamin k3 4 gm, Vitamin B1 2.5 gm, Vitamin B2 5 gm, Vitamin B6 4 gm, Nicotinic Acid 40 gm, Vitamin B12 12 mg, Pantothenic Acid 12.50 gm, Folic Acid 800 mg, Biotin 400 mg, Cobalt 400 mg, Iron 60 gm, Copper 10 gm, Iodine 400 gm, Manganese 60 gm, Zinc 50 gm, Selenium 150 mg, DL-Methionine 10 gm, L-Lysine 8 gm, Anti-Oxidant 10 gm, Carrier (Calcium Carbonate) q.s. to Kg 2.50	25kg, 50kg
190-19-(16)-011	AM GS Premix	Each 2.5 Kg Contains: Vitamin A 12,000,000 IU, Vitamin D3 2500,000 IU, Vitamin E 16 gm, Vitamin k3 2 gm, Vitamin B1 2 gm, Vitamin B2 5 gm, Vitamin B6 3 gm, Nicotinic Acid 25 gm, Pantothenic Acid 12 gm, Vitamin B12 10 gm, Folic Acid 1 gm, Biotin 50 gm, Cobalt 400 mg, Copper 8 gm, Iron 32 gm, Iodine 800 mg, Manganese 60 gm, Zinc 45 gm, Selenium 150 mg, DL-Methionine 50 gm, L-Lysine 30 gm, Carrier (Calcium Bi Carbonate) q.s to 2.5 Kg, Antioxidant 10 gm	25kg, 50kg
190-19-(16)-012	AM Breeder	Each 2.5 Kg Contains: Vitamin A 15,500,000 IU, Vitamin D3 3,500,000 IU, Vitamin E 30 gm Vitamin K3 4 gm, Vitamin B1 2.5 gm, Vitamin B2 10 gm, Vitamin B6 5 gm Vitamin B12 15 mg, Nicotinic Acid 40 gm, Pantothenic Acid 15 gm, Folic Acid 1 gm, Biotin 150 mg, Cobalt 500 mg, Iron 40 gm, Copper 10 gm, Iodine 1 gm, Manganese 60 gm, Zinc 80 gm, Selenium 200 mg, DL-Methionine 50 mg, L-Lysine 30 gm, Carrier (Calcium Carbonate) q.s to 2.5 kg, Antioxidant (Ethoxyquin) 10 gm	25kg, 50kg
190-19-(16)-013	Q-Zyme Plus	Each gm Contains: Pepsin 50 mg, Pancreatin 100 mg, Lipase 10 mg, Cellulose & concentrated enzyme 20 mg	100gm, 500gm, 1kg
190-19-(16)-014	AM Toxifree	Each 10 ml Contains: Calcium Chloride 5 mg, Sodium Selenite 3 mg, Zinc Chloride 2 mg Copper Sulphate 1 mg, Citric Acid 0.5 mg, Phosphoric Acid 5.0 mg, Lactic Acid 0.5 mg a	100ml, 500ml, 1L
190-19-(16)-015	Amvit ES	Each ml Contains: Vitamin-E Acetate BP 100 mg, Sodium Selenite BP 0.5 mg	100ml, 500ml, 1L
190-19-(16)-016	Amvit DB	Each 1 Kg Contains: Vitamin A 6,000,000 IU, Vitamin D3 20,000 IU, Vitamin E 0.75 gm, Vitamin K3 0.35 gm, Vitamin B1 0.15 gm, Vitamin B2 0.20 gm, Vitamin B6 0.01 gm, Vitamin B12 0.001 gm, Nicotinic Acid 1.25 gm, Pantothenic Acid 0.5 gm, Choline Chloride 25.0 gm, DL-Methionine 10.0 gm	500gm, 1kg, 2kg
190-23-(06)-017	Calplus Oral	Each 20 ml Contains: Calcium 325.6 mg, Phosphorus 167.7 mg, Magnesium 20 mg, Vitamin B12 20 mcg, Vitamin D3 1600 IU, Sucrose 5 gm, Strawberry Q.S.	500ml, 1L, 5L.

190-23-(06)-018	Apitazym	Each 100 gm Contains : Ammonium bicarbonate BP 25.0 gm, Nux Vomica BP 7.0 gm, Sodium bicarbonate BP 65.0 gm, Gentian Powder BP 1.5 gm, Ginger Powder BP 1.5 gm	20gm, 100gm, 500gm, 1kg
190-23-(06)-019	Acidine PH	Each Ltr. Contains: Orthophosphoric Acid 0.1575 gm, Propionic Acid 0.01 gm, Acetic Acid 0.25 gm, Lactic Acid 0.1 gm, Citric Acid 0.075gm, Formic Acid 0.030 gm	100ml, 500ml, 1L, 25L.
190-23-(06)-020	Hycal Plus	Each 100 gm Contains: Elemental Calcium 4.20 gm, Elemental Phosphorus 1.50 gm, Vitamin C 600 mg, Vitamin D3 40,000 IU, Vitamin B12 1000 Mcg, Citric Acid 27 gm, Excipients qs to 100 gm	500gm, 1kg
190-23-(06)-021	Zinc M Liquid	Each 100 ml Contains: Zinc Sulphate Monohydrate 2 gm, & DL-Methionine 0.1 gm	100ml, 500ml, 1L, 5L
190-23-(06)-022	Alvit-E	Each ml Contains : Vitamin E Acetate BP 200 mg	100ml, 500ml, 1L

Imported Finished Products List:

Sl No	Name of imported Products	Brand name of Al-Madina	Name of Country
1	Acidine pH	Acidine PH	Italy
2	Layer premix	Amcom Layer Premix	Italy
3	Aminosol	Amino Sol Liquid	Italy
4	Apsorb	Apsorb	Singapore/Belgium
5	Aqua Richer	Aqua Richer	India
6	Bronchimax	Bronchimax Liquid	Belgium
7	Avipharm ND	Avipharm ND	Slovak Republic
8	Bursipharm	Burshiparm	Slovak Republic
9	Pestipharm B1	Pestipharm B1	Slovak Republic
10	Bronchipharm	Bronchipharm	Slovak Republic
11	BKC Aqua	BKC Aqua	India
12	Calpro D +	Calpro D +	India
13	Choline Chloride	Choline Choride	China
14	DCP	DCP	China
15	MCP	MCP	China
16	DL-Methonine	DL-Methonine	Germany/China
17	Good Cleaner	Good Cleaner	S. Korea
18	Gaspel	Gaspel Powder	India
19	Gutbac	Gutbac	India
20	Hepaton	Hepaton Liquid	Italy
21	Hyvit ADE	Hyvit ADE Liquid	Singapore/Belgium
22	Hyvit DB	Hyvit DB Powder	Belgium
23	Hyvit ES Plus	Hyvit - ES Plus	Singapore/Belgium
24	Hyvit Fort WS	Hyvit Fort WS Powder	Singapore/Belgium
25	Immunity stim	Immunity Stim Liquid	Italy
26	Polgro	Polgro	India
27	Livtor	Livtor Liquid	India
28	L-Threonine	L-Threonine	China
29	L-Lysine	L-Lysine	China
30	Madina Zeo	Madina Zeo	Indonesia

31	Mould Fix	Mould Fix	Singapore/Belgium
32	Multimixzyme	Multimixzyme	Germany
33	Nephro - Guard	Nephro- Guard	India
34	NL 100 Fat	NL 100 Fat	Malaysia
35	Nu3link Xls	Nu3link Xls	Belgium
36	Nu3phos	Nu3phos	Belgium
37	Pure - Oxy Powder	Pure - Oxy Powder	China
38	Pure - Oxy Tablet	Pure - Oxy Tablet	China
39	Pure-Yucca	Pure-Yucca	India
40	Q-Zyme Plus Powder	Q-Zyme Plus Powder	India
41	Salmokil	Salmokil	Singapore/Belgium
42	Toxifree Liquid	Toxifree Liquid	India
43	Toxin Binder	Toxin Binder	Singapore/China
44	Grozyme WSP	Grozyme WSP	India
45	Nicoli WSP	Nicoli WSP	India
46	Niltox Liquid	Niltox Liquid	India
47	Gropti-Z Liquid	Gropti-Z Liquid	India
48	Liverguard +	Liverguard +	India
49	Zenotox Powder	Zenotox Powder	India
50	M-kolin Powder	M-kolin Powder	India
51	Viru check	Viru check	India
52	Antimast Powder	Antimast Powder	India
53	Bovipro Bolus	Bovipro Bolus	India
54	Orioil	Orioil	India
55	Panavis Oral solution	Panavis Oral solution	India
56	Diacell R	Diacell R	India
57	Norgain powder	Norgain powder	India
58	Bictoria	Bictoria	Netherland



Product List Human Division:

Antibiotic & Anti-Fungal				
Sl. No.	Products Name	Generic Name with Strength	Dosages Form	Remarks
1	Amiphin 1 gm IV Injection	Sterile Ceftriaxone Sodium USP 1.19 gm eqv. to Ceftriaxone 1 gm	Injection	
2	Amiphin 2 gm IV Injection	Sterile Ceftriaxone Sodium USP 2.38 gm eqv. to Ceftriaxone 2 gm	Injection	
3	Prex-3 200 Capsule	Cefixime (as Cefixime Trihydrate USP) 200 mg	Capsule	
4	Prex-3 400 Capsule	Cefixime (as Cefixime Trihydrate USP) 400 mg	Capsule	
5	Prex-3 PFS	Cefixime (as Cefixime Trihydrate USP) 100 mg/5ml	PFS	
6	Claviator-CV 250 Tablet	Cefuroxime (as Cefuroxime Axetil USP) 250 mg + Clavulanic Acid (as Potassium Clavulanate BP) 62.50 mg	Tablet	
7	Claviator-CV 500 Tablet	Cefuroxime (as Cefuroxime Axetil USP) 500 mg + Clavulanic Acid (as Potassium Clavulanate BP) 125 mg	Tablet	
8	Claviator -CV PFS	Cefuroxime USP 125 mg + Clavulanic Acid 31.25 mg/5 ml Powder For Suspension	PFS	

9	Thoraz 250 Tablet	Azithromycin Dihydrate USP 262.015 mg eqv.to Azithromycin 250 mg	Tablet	
10	Thoraz 500 Tablet	Azithromycin Dihydrate USP 524.03 mg eqv.to Azithromycin 500 mg	Tablet	
11	Thoraz PFS	Azithromycin 7.5% bitter less Powder (Ready Mix) Pharma grade 53.333 gmeqv.to Azithromycin 4 gm	PFS	
12	Cipex 250 Tablet	Ciprofloxacin Hydrochloride USP 291.106 mg eqv.to Ciprofloxacin	Tablet	
13	Cipex 500 Tablet	Ciprofloxacin Hydrochloride USP 582.212 mg eqv.to Ciprofloxacin 500.00 mg	Tablet	
14	Cipex 750 Tablet	Ciprofloxacin Hydrochloride USP 873.318 mg eqv. to 750mg Ciprofloxacin	Tablet	
15	Cipex PFS	Ciprofloxacin 20% Pellets /Granules Pharma Grade 25gm eqv. to Ciprofloxacin 5gm/100ml	PFS	
16	Isovox 500 Tablet	Levofloxacin Hemihydrate USP 512.469 mg eqv. to Levofloxacin 500 mg	Tablet	
17	Terbiheal Tablet	Terbinafine Hydrochloride USP 281.3 mg eqv. to Terbinafine 250 mg	Tablet	
18	Terbiheal Cream	Terbinafine Hydrochloride USP 11.25 mg eqv. to Terbinafine 10 mg	Cream	
19	Flumazole 50 Capsule	Fluconazole USP 50 mg	Capsule	
20	Flumazole 150 Capsule	Fluconazole USP 150mg	Capsule	
21	Micoheal Oral Gel	Miconazole BP 20mg/gm	Oral Gel	
Analgesic, Antipyretic & Skeletal Muscle Relaxant				
1	Anaprox Tablet	Esomeprazole Magnesium Trihydrate USP 23.88 mg eqv.to Esomeprazole 20 mg + Naproxen BP 500mg	Tablet	
2	Ampol 500 Tablet	Paracetamol BP 500mg	Tablet	
3	Ampol Plus Tablet	Paracetamol BP 500mg + Caffeine Anhydrous BP 65mg	Tablet	Relaunched
4	Ampol XR Tablet	Paracetamol BP 665 mg	Tablet	Newly Introduced
5	Claim ER Tablet	Aceclofenac BP 200mg	Tablet	
6	Claim 100 Tablet	Aceclofenac BP 100mg	Tablet	
7	Coxtop 60 Tablet	Etoricoxib INN 60mg	Tablet	
8	Coxtop 90 Tablet	Etoricoxib INN 90mg	Tablet	
9	Coxtop 120 Tablet	Etoricoxib INN 120mg	Tablet	
10	Diclofast SR Capsule	Diclofenac Sodium SR pellets 40 % w/w Pharma Grade 250 mg eqv. to Diclofenac Sodium BP 100 mg	Capsule	
11	Tufexil Tablet	Tolfenamic Acid BP 200mg	Tablet	
12	Xiroket 10 Tablet	Ketorolac Tromethamine USP 10 mg	Tablet	
13	Xiroket IM/IV Injection	Ketorolac Tromethamine USP 30 mg	Injection	

14	Xiroket IM/IV Injection	Ketorolac Tromethamine USP 60 mg/2ml	Injection	Unintroduced
15	Zerofen 100 Tablet	Ketoprofen BP 100mg	Tablet	
16	Zerolent 10 Tablet	Baclofen USP 10mg	Tablet	
Anti-Histamine, Bronchodilator & Leukotriene Receptor Antagonist				
1	Cetmax 10 Tablet	Cetirizine Dihydrochloride BP 10mg	Tablet	
2	Rynofex 120 Tablet	Fexofenadine HCl USP 120 mg	Tablet	
3	Rynofex 180 Tablet	Fexofenadine HCl USP 180 mg	Tablet	
4	Ventilast 10 Tablet	Montelukast Sodium USP 10.40 mg eqv. to Montelukast 10 mg	Tablet	
5	Freeway 200 Tablet	Doxophylline INN 200 mg	Tablet	Newly Introduced
6	Freeway 400 Tablet	Doxophylline INN 400 mg	Tablet	Newly Introduced
Anti-Ulcerant, Gastroprokinetic, & Anti-Spasmodic				
1	Gastrazole 20 Tablet	Rabeprazole Sodium INN 20mg	Tablet	
2	Raceper 20 Capsule	Esomeprazole Magnesium Trihydrate enteric coated pellets 8.5% Pharma Grade 235.294 mg eqv. to Esomeprazole 20 mg	Capsule	
3	Raceper 40 Capsule	Esomeprazole Magnesium Trihydrate enteric coated pellets 8.5% Pharma Grade 470.588 mg eqv. to Esomeprazole 40 mg	Capsule	
4	Raceper 20 Tablet	Esomeprazole Magnesium Trihydrate USP 23.88 mg eqv. to Esomeprazole 20 mg	Capsule	
5	Prilosec 20 Tablet	Pantoprazole Sodium Sesquihydrate BP 22.55 mg eqv. to Pantoprazole 20 mg	Tablet	
6	Prilosec 40 Tablet	Pantoprazole Sodium Sesquihydrate BP 45.10 mg eqv. to Pantoprazole 40 mg	Tablet	
7	Zolat 20 Capsule	Omeprazole enteric coated pellets 8.5% Pharma Grade 235.294 mg eqv. to Omeprazole BP 20 mg	Capsule	
8	Zolat 40 Capsule	Omeprazole enteric coated pellets 8.5% Pharma Grade 470.588 mg eqv. to Omeprazole BP 40.00 mg	Capsule	
9	Almigut Tablet	Domperidone Maleate BP 12.72 mg eqv. to Domperidone 10 mg	Tablet	
10	Freespa 50 Tablet	Tiemonium Methyl Sulphate INN 50mg	Tablet	
Vitamins & Minerals				
1	Alovit BZ Tablet	Zinc Sulphate Monohydrate BP 27.45mg eqv. to Elemental Zinc 10 mg + Thiamine Mononitrate (B1) BP 5mg + Riboflavin (B2) BP 2.75mg + Pyridoxine HCl (B6) BP 2mg + Nicotinamide (B3) BP 20 mg	Tablet	
2	Alovit-C 250 Chewable Tablet	Ascorbic Acid BP 100mg + Sodium Ascorbate BP 168.75 mg eqv. to Ascorbic Acid 150mg	Chewable Tablet	Unintroduced

3	Alovit Gold Tablet	Multivitamin & Multimineral (A-Z)	Tablet	Newly Introduced
4	B3 Tablet	Thiamine Mononitrate USP 100 mg + Pyridoxine Hydrochloride BP 200 mg + Cyanocobalamin BP 200 mcg	Tablet	
5	Bonwell-D Tablet	Calcium Carbonate BP 1250 mg eqv.to elemental Calcium 500 mg + Vitamin D3 BP 200IU	Tablet	
6	Coralium -D Tablet	Calcium Carbonate (Coral Calcium) BP 1250 mg eqv.to elemental Calcium 500mg + Vitamin D3 BP 200 IU	Tablet	
7	Carbium Capsule	Carbonyl Iron, Zinc , Vitamin B Complex, Folic Acid and Vitamin C Blended Pellets Pharma Grade 440mg	Capsule	
8	Zinc Kid Dispersible Tablet	Zinc Sulfate Monohydrate BP 54.90 mg eqv. to elemental Zinc 20mg	Dispersible Tablet	
Anti-Epileptic				
1	Algaba 50 Capsule	Pregabalin INN 50mg	Capsule	Newly Launched
2	Algaba 75 Capsule	Pregabalin INN 75mg	Capsule	Newly Launched
3	Algaba 150 Capsule	Pregabalin INN 150mg	Capsule	Unintroduce
Lipid Lowering agent, Fibrates & Anti-Hypertensive				
1	Atomax 10 Tablet	Atorvastatin Calcium Trihydrate USP 10.85 mg eqv. to Atorvastatin 10 mg	Tablet	Newly Launched
2	Atomax 20 Tablet	Atorvastatin Calcium Trihydrate USP 21.7 mg eqv. to Atorvastatin 20 mg	Tablet	Newly Launched
3	BC-Card Tablet	Amlodipine Besilate BP 694mg eqv. to Amlodipine 5 mg + Atenolol BP 50mg	Tablet	Newly Launched
4	Fenogard 200 Capsule	Fenofibrate (micronised) BP 200mg		Fired
Anxiolytic & Antidepressant				
1	Fulrest Tablet	Flupentixol Dihydrochloride BP 584 mcg eqv. to Flupentixol 500 mcg + Melitracen Hydrochloride INN 11.25 mg eqv. to Melitracen 10 mg	Tablet	
Anthelmintic				
1	ABZ 400 Chewable Tablet	Albendazole USP 400mg	Chewable Tablet	Unintroduce
Urinary Alkalinizing Agent & Urinary Retention				
1	Alken Solution	Potassium Citrate BP 30 gm + Citric Acid Monohydrate BP 5gm/100ml	Oral Solution	
2	Uripay 100 Tablet	Flavoxate Hydrochloride BP 100 mg	Tablet	Fired

3	Uripay 200 Tablet	Flavoxate Hydrochloride BP 200 mg	Tablet	Fired
4	Urivent Capsule	Tamsulosin Hydrochloride SR pellets 0.2% Pharma Grade 200 mg eqv. to Tamsulosin Hydrochloride 0.4mg	Capsule	Fired
Topical Preparation				
1	Alivio Cream	Methyl Salicylate BP 150mg + Menthol BP 100mg/gm	Cream	
2	Alivio Extra Cream	Camphor USP 4g + Menthol BP 10g + Methyl Salicylate 30g/100g	Cream	
3	Miaz Cream	Miconazole Nitrate BP 20mg/gm	Cream	
4	Spotless Cream	Hydroquinone USP 40mg/gm	Cream	
Hand Sanitizing Preparation				
1	Cleanex Hand Sanitizer Gel	Ethyl Alcohol BP 66ml + Isopropyl Alcohol BP 3.5ml/100ml	Hand Sanitizer	Fired
2	Hexil Hand Sanitizer	Isopropyl Alcohol (99.80%) BP 75.15 ml + Hydrogen peroxide (3%) BP 4.17ml + Glycerol (98%) BP 1.45ml	Hand Sanitizer	Fired

Upcoming new Product list (As per future planning):

Agro vet Division:

1	Retivit- A	Each gm contains : Vitamin-A Acetate BP 10%	100 gm, 500 gm, 1 kg
2	AM Immunity Stim	Each 2.5 kg contains: Vitamin E 25.000 mg, Vitamin C 2.100 mg, L-Glycine 10.000 mg, Selenium E 8 (Sodium selenite) 0.5 mg, Manganese E 5 (manganese sulphate) 500 mg, Natural products - botanically defined Rosemary essential oil 10.000 mg, Thyme essential oil 10.000 mg, Eucalyptus essential oil 10.000 mg, odium chloride 1.250 mg Potassium chloride 500 mg, Yeast extract 50.000 mg, Polysaccharides 20.000 mg Demineralised water s. to. 1.000 mg	100 ml, 500 ml, 1 Ltr, 25 ltr.
3	AM Apsorb	Hydrated Sodium Calcium Aluminosilicate (HSCAS)	25 kg
4	AM Methionine	AM-Methionine powder contains : DL-Methionine 99%	25 kg
5	AM Lysine	L - Lysine Mono Hydrochloride 98.5%	25 kg
6	AM Threonine	L-Threonine 98.5%	25 kg
7	AM Mold Fix	Calcium Propionate 400 gm, Citric Acid 100 gm, Sorbic Acid 15 gm Formic Acid 50 gm, Sepiolite 430 gm	20 kg, 25 kg
8	AM Salmokil	Formic Acid 33,5 %, Propionic Acid 14 %, Citric Acid 6 %, Lactic Acid 0,78 %	20 kg, 25 kg
9	Potentzyme Plus	Each kg contains : 6-Phytase 150 000 FYT, Serin-Protease 375 000 PROT, Endo 1,4 Beta Xylanase 1875 000 U, Endo 1,4 Beta Glucanase 1700 000 U, Endo 1,3(4) Beta Glucanase 220 000 U, Alpha Amylase 37500 U, Bacillolysin 42000 U, Diatomaceous earth, purified 150,000 mg	20 kg, 25 kg

10	Nephroguard	Each 100 ml. contains : Vitamin A 15000000 UI, Vitamin D/Vitamin D3 200000 UI, Vitamin E 8000 mg, (as all-rac-alpha-tocopheryl acetate) Vitamin B1/Thiamine mononitrate 1800 mg, Vitamin B2/Riboflavin-5'-phosphate ester monosodium salt 1300 mg, Vitamin B6/Pyridoxine hydrochloride 800 mg, Vitamin B12/Cyanocobalamin 12 mg, Nicotinic acid/ Nicotinic acid amide (nicotinamide) 12500 mg, Vitamin C/L-Ascorbic acid 22000 mg, Vitamin K (as Menadione sodium bisulfite) 1000 mg, Pantothenic acid/D-panthenol 5000 mg, Folic acid 250 mg	100 ml, 500 ml, 1 Ltr
11	AM Bronchimax	Sodium Chloride 30 %, Pentose Sugar 0.5 %, L-cysteine 10 %, Acetic acid 2.5 % Lactic acid 1.7 %, Vitamin A 1,000,000 IU, Vitamin E 10 %, Essential Oil 35 %	100 ml, 500 ml, 1 Ltr
12	AM Polgro	Each 100 gm contains : Vitamin B1 100 mg, Vitamin B2 80 mg, Vitamic C 100 mg, Zinc Chloride 5 gm, Magnesium Chloride 3gm, Calcium 15 gm, Phosphorus 7 gm	25 Kg
13	Nephrovet	Each gm contains : Methenamine 950 mg, Vitamin B1 8 mg, Vitamin B2 1 mg, Vitamin K3 (MSB) 2gm	100 gm, 500 gm, 1 kg
14	AM Livtor	Each Ltr. contains : Vitamin B1 200 mg, Vitamin B2-5-phosphate 200 mg, Vitamin B6 200 mg, Vitamin B12 200 mg, Pantothenol 1100 mg, Niacin 6000 mg, Folic Acid 30 mg Betaine 4000 mg, Choline Chloride 5000 mg, L-Glycine 5000 mg, Vitamin K 65 mg, Inositol 100 mg, L-Lysine HCl 8000 mg, DL-Methionine 5000 mg, L-Threonine 1000 mg, L-Tryptophan 250 mg	100 ml, 500 ml, 1 Ltr
15	Fera Sol Oral Solution	Each 100 ml Contains: Ferrous Sulfate 50 ml, Copper sulfate 20 ml, Zinc Sulfate 20 ml, Cobalt Sulfate 10 ml & Vitamin B12 5 ml.	500ml, 1L & 3L.
16	Renal Cleaner	Each 100 gm Contains : Zyloprim (Allopurinol) 5 gm, Vitamin A 2 gm, Vitamin B2 0.05 gm, Vitamin C 2 gm, Vitamin K3 0.1 gm.	100gm, 500gm, 1kg.
17	Bloat seal	Each 100 ml contains : Simethicone - 1.5% W/V, Dill oil - 0.5% V/V, Calcium propionate - 25 gm, Cobalt carbonate - 5 mg, DL-Methionine - 2 gm, Pyridoxine HCl - 20 mg, Silicon dioxide - 0.625 gm, Nux vomica - 200 mg, Water q.s.to - 100 ml.	100ml, 250ml, 500ml, 1L
18	VD Cure Powder	Each 100 gm Contains: Zinc Sulphate 600 mg, Vitamin C 3000 mg, Potassium Iodide 200 mg, Glutamic Acid 1500 mg, Vitamin E 2000 mg, Cobalt 10 mg, Riboflavin 10 mg, Selenium 2 mg.	100gm, 500gm, 1kg
19	Fatty max Powder	Each gm Contains: Butaphosphan 100 mg, Cyanocobalamin 50 mcg.	100gm, 500gm, 1kg

20	Solomin Oral	Each ml Contains: Phosphorus 2 mg, Manganese 10.8 mg, Iron 9.7 mg, Zinc 10 mg, Sodium 5.5 mg, Cobalt 124 mcg, Copper 5.6 mg, Calcium 15.3 mg.	100ml, 500ml, 1L, 5L
21	Betasol vet Oral	Each ml Contains: Betain 250 mg, Vitamin C 90 mg, KCl 2 mg, Magnesium Chloride Hexahydrate 4 mg, Potassium Chloride Dihydrate 40 mg, NaCl 20 mg.	100ml, 500ml, 1L
22	Hyvit BC WS	Each 100 gm Contains: Ascorbic acid 0.50 gm, Riboflavin Sodium- 5 phosphate 0.40 gm, Thiamine 0.20 gm, Pyridoxine 0.15 gm, Nicotinamide 0.75 gm, Calcium D Pantothenate 0.45 gm, Vit B12 0.001 gm, Folic acid 0.025 gm, Biotin 2% 0.0015 gm, Dextrose anhydrase 97.53 gm.	100gm, 500gm, 1kg.
23	Multi Vitamin WS	Each Kg Contains: Vitamin A 10 MIU, Vit D3 2.5 MIU, Vit E 20 gm, Vit K3 16 gm, Vit B1 12 gm, Vit B2 32 gm, Vit B6 12 gm, Vit B12 mg, DL- Methionine 10 gm, L-Lysine 25 gm, Nicotinamide 20gm, Calcium D Pantothenate 18.4 gm, Biotin 100 gm, Folic acid 1.2 gm, Vit C 300 gm.	100gm, 500gm, 1kg
24	Toxifree Plus	Each Ltr. Contains: Formic acid 70 gm, Ortho-Phosphoric Acid 70 gm, Lactic acid 10 gm, Sorbic Acid 1 gm, Fumaric Acid 20 gm, Malic acid 10 gm, Citric Acid 40 gm, Copper Penta Sulphate 10 gm, Essential oil (Thymol) 1 gm, Yeast of Saccharomyces Cerevisiae (Beta glucan and Mannan oligosaccharide) 70 gm, Emulsifiers 50 gm.	500ml, 1L
25	Nephroguard Oral	Each 100 ml Contains : Zylprim (Allopurinol) 5 gm, Methenamine 25 gm, Vitamin A 2 gm, Vitamin B2 0.05 gm, Vitamin C 2 gm, Vitamin K3 0.1 gm	100ml, 500ml, 1L
26	Selox D Bolus	Each Bolus Contains: Vitamin A 100000 IU, Vitamin E 30 IU, Vitamin C 200 mg, Vitamin D3 10000 IU, Selenium 1 mg.	35 Boli in pot, 70 Boli in pot
27	Bonvit D Powder	Each gram Contains: Vitamin D (Cholecalciferol) 1,00,000 IU	100gm, 500gm, 1kg
28	Diluent for Vaccine	Sterile water for vaccine dilution	40ml
29	Nixin-Vet Injection	500 mg/10 ml	10ml, 50ml, 100ml
30	Tocin-Vet Injection	10 IU/ml	10ml, 50ml, 100ml
31	Clomec Vet Injection	500 mg + 50 mg /5ml	10ml, 50ml, 100ml
32	Sulmidin-Vet Injection	33.3 gm / 100ml	10ml, 50ml, 100ml
33	Paramel Vet Injection	200mg+1.5gm/10ml	10ml, 50ml, 100ml
33	Bcom-Vet Injection	Thiamine HCl BP 250 mg + Riboflavin (Riboflavin Sodium Phosphate BP) 20 mg + Pyridoxine HCl BP 50 mg + Nicotinamide BP 500 mg + D-Panthenol USP 25 mg / 10 ml Injection	10ml, 50ml, 100ml

35	Diphen Vet Injection	Diphenhydramine HCl 20 mg / ml	10ml, 50ml, 100ml
36	NS-Vet Plus WSP	Neomycin Sulfate BP 700 mg/ gm	100gm, 500gm, 1kg
37	Marboquin Vet Bolus	Marbofloxacin 50 mg / Bolus	10x2s, 4x5s
38	Mineral Bolus	Copper 100 mg, Cobalt 4 mg, Manganese 50 mg, Zinc 300 mg, Iodine 5 mg, Iron 100 mg and Selenium 1 mg per Bolus	10x2s, 4x5s
39	Marboquin-Vet Oral Solution	Each 100 ml oral solution contains Marbofloxacin BP 10 g	100ml, 500ml, 1liter
40	Bcom-Vet Plus Injection	Each ml contains Thiamine HCl BP 75 mg, Riboflavin (as Sodium Phosphate) BP 2 mg, Pyridoxine HCl BP 5 mg, Cyanocobalamin BP 120 mcg, Niacinamide USP 100 mg, D Panthenol BP 20 mg, Ferric Amonium Citrate USP 15 mg, Cobalt Gluconate Ph. Grade 0.7 mg and Copper Gluconate USP 0.2 mg	10ml, 50ml, 100ml

Human Division:

Sl. No.	Products Name	Dosages Form	Remarks
1	Ceftriaxone 500 mg	Injection	
2	Meropenem 1 gm IV	Injection	
3	Flucloxaclin BP 125mg/5ml	PFS	
4	Flucloxaclin BP 500 mg	Capsule	
5	Dexlansoprazole INN 30mg	Capsule	
6	Dexlansoprazole INN 60mg	Capsule	
7	Itraconazole USP 100mg	Capsule	
8	Fexofenadine Hydrochloride USP 30mg/5ml	Suspension	
9	Sodium Alginate BP 5gm + Sodium Bicarbonate BP 2.67gm + Calcium Carbonate BP 1.60gm/100ml	Suspension	
10	Ketotifen Fumarate BP 1.380 mg eq. to Ketotifen 1 mg/5ml	Syrup	
11	Zinc Sulphate Monohydrate USP 27.44 mg eqv. to Elemental Zinc 10mg/5ml	Syrup	
12	Butamirate Citrate INN 7.5mg/5ml	Syrup	
13	Ambroxol HCl BP 15mg/5ml	Syrup	
14	Cetirizine Dihydrochloride BP 5mg/5ml	Syrup	
15	Guaifenesin BP 100mg, Levomenthol BP 1.1 mg and Diphenhydramine Hydrochloride BP 14 mg /5ml	Syrup	
16	Dextromethorphan Hydrobromide 6.5 mg +Levomenthol 2 mg+ Diphenhydramine Hydrochloride 14 mg/5ml	Syrup	

18	Domperidone BP 5mg/5ml	Suspension	
19	Clotrimazole BP 10mg/gm	Cream	
20	Econazole Nitrate BP 10mg/gm	Cream	
21	Econazole Nitrate BP 10 mg + Triamcinolone Acetonide BP 1 mg/gm	Cream	
22	Montelukast Sodium USP 5.20 mg eqv. to Montelukast 5 mg	Tablet	
23	Moxifloxacin USP 400mg	Tablet	
24	Rupatadine EP 10 mg	Tablet	
25	Bilastine INN 20 mg	Tablet	
26	Ondansetron HCl Dihydrate USP 9.976 mg eqv. to Ondansetron 8 mg	Tablet	
27	Sodium Picosulfate BP 10 mg	Tablet	
28	Calcium Carbonate (Algae source) 1250 mg eqv. to elemental Calcium USP 500mg + Vitamin D3 USP 200 IU	Tablet	
29	Vildagliptin INN 50mg	Tablet	

Export in Process of Pharma Product:

Al-Madina Pharmaceuticals Ltd is producing good quality products for human health servicing. We have good at management, sophisticated technology, well set up laboratory etc. We are following all compliance for operation of factory and development of products. Day by Day we are also increasing market share of the local Pharma market significantly. We are trying to do export of Pharma products. At this moment, we have developed two buyers Hejaz Ltd, Afghanistan and Al-Zubaidi Stores, Yemen as well as completed agreement with the mentioned buyers. We are waiting for receiving the purchase order from buyers. The buyers have interested to take for the following products:

Sl. No	Brand name	Generic Name	Pack Size	Dosage Form
1	Almight	Domperidone Malcate BP12.72 mg cq.v.to Domperidone 10mg	100s	Tablet
2	Alovit BZ Tab.	Zinc Sulphate Monohydrate BP 27.45mg Eqv.to Elemental Zinc 10mg + Thiamine Mononitrate (B1)BP 5mg +Riboflavin (B2) BP2.75mg +Pyridoxine HCl (B6) BP 2mg +Nicotinamide (B3)BP20 mg	30s	Tablet
3	Ampol 500Tab	Paracetamol BP 500mg	300s	Tablet
4	Ampol Plus Tablet	Paracetamol BP 500mg+ Caffeine Anhydrous BP65mg	200s	Tablet
5	Bonwell D	Calcium Carbonate BP 1250 mg eqv. To elemental Calcium 500mg+Vitamin D3 BP 200IU	15s	Tablet
6	Bonwell D	Calcium Carbonate BP 1250 mg eqv. To elemental Calcium 500mg+Vitamin D3 BP 200IU	30s	Tablet
7	Fulrest Tab.	Flupentixol 500Mg +Melitracen 10 mg	100s	Tablet

8	Prex-3	Cefixime (As Cefixime Trihydrate USP) 100mg/5ml	30ml	PFS
9	B3	Thiamine Mononitrate 100mg +Pyridaxine Hydrochloride 200 mg + Cyanocobaiamine 200 mcg	60s	Tablet
10	ventilast 10	Montelukast 10 mg	30s	Tablet
11	Thoraz 500	Azithromyon 500mg	12s	Tablet
12	Rynofex 120	Fexofenadine HCl 120 mg	50s	Tablet
13	Rynofex 180	Fexofenadine HCl 180 mg	30s	Tablet
14	ABZ 400 Chewable	Albendazole 400mg	50s	Tablet

Product Performance based on Sales:

Top Ten Products list:

Agro vet Division:

1. NS-Vet Powder
2. Tilvet Liquid
3. Set-3 Powder
4. Alcipro-vet Solution
5. Anticocci-K Powder
6. T-Zuril Liquid Vet
7. Aminosol Liquid
8. LV-Vet Powder
9. Alenro Vet Solution
10. FC-Vet Oral Solution



Human Division:

1. Zolat 20 Capsule
2. Thoraz 500 Tablet
3. Raceper 20 Capsule
4. Claviator-CV 250 Tablet
5. Anaprox Tablet
6. B3 Tablet
7. Prex-3 200 Capsule
8. Tufexil
9. Ventilast 10 Tablet
10. Coralium-D 30's Tablet



Extra –Ordinary gain or Loss:

There is no Extra –Ordinary gain or loss during the year which require adjustment or disclosure in the financial statement.

Related Party Transaction:

During the year under audit the company carried out no transaction with related parties in normal course of business. It is disclosed in the notes no 32.02 to the financial statements for the year ended 30.06.2023 for short term employee benefits.

Utilization of proceeds through QIO:

Al-Madina Pharmaceuticals Ltd has raised Capital tk 5.00 Core through QIO .The utilization of proceed for raising Capital through QIO as at 30.09.2023 has Given Company Website Link :<https://almadinapharma.com>

Remuneration of Directors:

This information is incorporated in the notes No 32.02 to the financial statement.

Capacity Utilization

The overall capacity utilization of the plant operation during the year 2022-2023 has been presented hereunder:

Types of Machine	Unit	Installed Capacity per annum (291 working day/single shift)	Actual Production per annum	% of capacity utilization
Tablet	Pcs	436500000	305550000	70
Capsule	Pcs	167616000	100569600	60
Liquid	Liter	291000	203700	70
Liquid (External)	Bottle	2328000	232800	10
Powder	kg	145500	94575	65
Bolus	Pcs	29100000	17460000	60
semisolid (cream, ointment, gel)	Tube	2328000	1629600	70
PFS	Bottle	2328000	931200	40

Industry outlook and possible future development in the industry:

Pharmaceutical industry is one of the most promising sectors in Bangladesh. After the promulgation of local industry friendly Drug (Control) Ordinance in 1982 the scenario of pharmaceutical industries changed considerably. Now, after fulfilling the local demand, Bangladesh is exporting pharmaceutical products to over 100 countries of the world. There are still lots of space for Bangladesh to flourish in this sector. So, initiatives from the stakeholders are required to ensure the remarkable growth of pharmaceutical industries in Bangladesh. The pharmaceuticals industry of Bangladesh is driving to change by increasing per capita income, population growth, changing disease profile, lifestyle changed and rapid urbanization.

Financial Result (5 Years):

The Financial Result of the Company is hereunder:

Five Years Financial Information:

Revenue and Results from Operation:

Particulars	30.06.2023	30.06.2022	30.06.2021	30.06.2020	30.06.2019
Sales Revenue	685,624,856	668,965,108	556,164,433	371,565,576	228,664,494
Cost of Goods Sold	(404,897,888)	(398,296,705)	(350,825,289)	(260,240,946)	(181,035,094)
Gross Profit	280,726,968	270,668,403	205,339,144	111,324,630	47,629,400
Administrative & General Expenses	(32,783,093)	(35,512,458)	(29,353,052)	(18,144,030)	(13,616,162)
Marketing, Selling & Distribution Expenses	(199,671,749)	(188,954,187)	(132,404,722)	(63,562,187)	(28,882,358)
Operating Profit	48,272,126	46,201,758	43,581,370	29,618,413	5,130,880
Other Income	-	-	-	2,355	2,830
Financial Expenses	14,515,647	(12,321,155)	(12,808,039)	(14,987,617)	(4,801,804)
Net Profit / (Loss) for the year Before WPPF	33,756,479	33,880,603	30,773,331	14,633,151	331,906
Workers' Profits Participation Funds	(1,607,451)	(1,613,362)	(1,465,397)	(696,817)	-
Net Profit / (Loss) before Tax	32,149,027	32,267,241	29,307,934	13,936,334	331,906
Current tax	(5,897,504)	(9,680,172)	(8,792,380)	(4,529,309)	(1,371,987)
Deferred tax Income/(Expenses)	(1,085,353)	(2,848,529)	2,672,783	1,069,403	-
Net Profit / (Loss) after Income Tax	25,166,171	19,738,540	23,188,337	10,476,429	(1,040,081)
Other Comprehensive Income:		-	138,967,050	-	-
Revaluation Reserve		-	143,265,000	-	-
Less: Deferred Tax Liabilities on Revaluation Reserve		-	(4,297,950)	-	-
Total Comprehensive Income	25,166,171	19,738,540	162,155,387	10,476,429	(1,040,081)
Earnings Per Share Basic	1.57	1.30	33.99	34.92	(3.47)

Statement of Financial Position:

Particulars	30 june 2023	30 june 2022	30 june 2021	30 june 2020	30 june 2019
ASSETS					
Non-Current Assets	317,176,332	333,166,382	328,029,470	40,219,534	41,994,210
Property Plant and Equipment	299,895,672	317,322,205	315,447,070	40,219,534	41,994,210
Right-of- Use Asset (ROU)	14,259,760	15,844,178	12,582,400	-	-
Current Assets	322,700,893	214,101,090	144,709,219	126,150,719	45,393,168
Inventories	26,313,770	24,411,720	22,550,762	15,601,839	15,638,061
Inventory In Transit	3,277,085	3,133,256	1,592,498	6,577,781	2,463,692
Deferred Tax asset			3,742,186	1,069,403	-
Accounts and other Receivable	214,863,981	144,589,522	85,044,266	68,767,803	512,650
Advance Deposit & Pre-Payments	36,030,322	25,345,244	19,781,797	20,703,219	26,153,477
Cash and Bank Balances	42,215,736	16,621,348	11,997,710	13,430,674	625,288
TOTAL ASSETS	639,877,225	547,267,472	472,738,689	166,370,253	87,387,378
EQUITY AND LIABILITIES					
Equity attributable to the owners of the company	404,268,996	333,400,775	287,662,235	20,506,848	10,030,419
Share Capital	204,000,000	154,000,000	128,000,000	3,000,000	3,000,000
Retained Earnings	61,301,946	43,850,085	20,695,185	(2,493,152)	(12,969,581)
Share Money Deposit		-	-	20,000,000	20,000,000
Revaluation Reserve		138,967,050	138,967,050	-	-
Non-Current Liabilities	15,589,991	15,257,539	16,412,304	10,343,978	12,063,115
Long Term Loan from Bank	4,564,509	7874546	6,811,491	10,343,978	12,063,115
Deferred Tax Liabilities	8,787,596	3,404,293	4,297,950	-	-
Lease obligation (non-Current)	2,237,886	3,978,700	5,302,863	-	-
Current Liabilities & Provisions	220,018,240	198,609,159	168,664,150	135,519,427	65,293,844
Long Term Loan (Current Portion)	3,310,037	1,284,461			
Lease obligation (Current)	1,866,003	3,671,146	4,711,968	-	-
Short Term Loan	163,348,334	148,909,450	132,327,788	120,617,296	27,944,952
Accounts Payable	3,840,445	3,145,000	3,565,560	1,666,934	29,810,705
Liabilities for Expenses	21,911,378	21,754,562	17,894,467	7,333,902	6,166,200
Provision for income tax	25,742,043	19,844,539	10,164,367	5,901,296	1,371,987
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	639,877,225	547,267,472	472,738,689	166,370,253	87,387,378
Net Asset Value Per Share with Revaluation	19.82	21.65	22.47	-	-
Net Asset Value Per Share without Revaluation	13.00	12.63	11.62	68.36	33.43

Statement of Cash Flows:

Particulars	2022-2023	2021-2022	2020-2021	2019-20	2018-19
A. Cash Flow from Operating Activities	(26,323,262)	(8,401,604)	44,973,738	(75,065,338)	10,855,893
Cash from Customer	615,350,397	678,556,692	539,887,970	303,312,778	228,569,875
Cash paid to Suppliers, Employee and other Expenses	(632,629,033)	(68,0743,955)	(494,914,232)	(378,378,116)	(217,713,982)
Tax Paid	(9,044,626)	(6214341)			
B. Cash Flow from Investment Activities	(7,690,815)	(24,516,710)	(68,871,538)	(3,082,483)	(9,658,553)
Cash for Property ,Plant and Equipment	(2,690,815)	(24,516,710)	(68,871,538)	(3,082,483)	(9,658,553)
Paid for Building Construction work in Progress	(5000000)	-	-		
C. Cash Flow from Financing Activities	59,608,466	37,541,951	22,464,836	90,953,207	(1,127,933)
Cash for Long Term Liabilities	(1,284,461)	2,347,516	(3,532,487)	(1,719,137)	(1,127,933)
Lease obligation	(3545957)	(7,387,227)	(5,713,169)	-	-
Cash for Short Term Liabilities	14,438,884	16,581,662	11,710,492	92,672,344	-
Share Capital	50,000,000	26,000,000	40,000,000	-	-
Share Money	-	-	(20,000,000)	-	-
D.Net cash flow for the year (A+B+C)	25,594,389	4,623,638	(1,432,964)	12,805,386	69,407
E. Opening Cash and Cash Equivalents	16,621,348	11,997,710	13,430,674	625,288	555,881
F. Closing Cash and Cash Equivalents	42,215,736	16,621,348	11,997,710	13,430,674	625,288

Significant Information:

The significant information of the financial statements are stated as below:

Sl No.	Particulars	Year ended on 30 June 2023	Year ended on 30 June 2022
I	Earning per share (EPS)-Basic/ Weighted average	1.57	1.30
II	Earning per share (EPS)- Diluted	1.23	0.97
III	Net Asset Value (NAV) with Revaluation	40,42,68,995	33,34,00,774
iv	Net Asset Value (NAV) without Revaluation	26,53,01,945	19,44,33,724
v	NAV per share with revaluation	19.82	21.65
vi	NAV per share without revaluation	13.00	12.63
vii	Net Operating Cash Flow per share (NOCFPS)	-1.64	-0.55

"The details of the financial statements is available in the website <https://almadinapharma.com>"

Environmental Rule:

The Company maintains a high standard of pollution free environment as per GMP Regulations/Who/Government Laws.

Quality Rule:

The Company maintains a high quality management as per ISO 9001- 2015 Rules.

Credit Rating:

The ALFA has confirmed the credit rating for long term rating A- and for short term rating ST-2 on the basis of financial report as at 30.06.2022 and other relevant qualitative and quantitative information of the company.

Compliance of Financial Statement:

The financial statements have been meticulously prepared to adhere to the stipulations set forth by the Companies Act of 1994, the Securities and Exchange Rules of 2020, The Value Added Tax and Supplementary Duty Act, 2012, the Income Tax Act 2023 and pertinent local regulations. Furthermore, these statements have been designed in accordance with the guidelines of the International Financial Reporting Standard (IFRS) and the International Accounting Standards (IAS). These statements present fairly the company's state of affairs, the result of Operation, Cash flow and changes in equity.

Proper Books of Accounts:

Books of Accounts of the company have been maintained properly.

Accounting Policies:

The accounting principles and policies pertaining to significant components of the financial statements, as detailed below, have been consistently employed across all periods presented within these financial statements.

Presentation of Financial Statement:

The financial statements provided according to the guidelines of IAS 1: Presentation of Financial Statements. These financial statements consist of the following components:

- (a) Statement of Financial Position as at June 30, 2023.
- (b) Statement of Profit or Loss and Other Comprehensive Income for the period from July 1, 2022, to June 30, 2023.
- (c) Statement of Changes in Shareholders' Equity for the period from July 1, 2022, to June 30, 2023.
- (d) Statement of Cash Flows for the period from July 1, 2022, to June 30, 2023.
- (e) Statement of Notes, which includes a summary of significant accounting policies and explanatory information.

Internal Control:

The internal Control System:

The internal Control System of Al-Madina Pharmaceuticals Ltd has been designed to save the risk, Material Loss, Accountability and record transaction properly. The board is reviewing its effective ness in accordingly.

Minority Shareholders Interest:

The Board hereby confirmed that the interest of minority shareholders have been fully protected in the company.

Going Concern:

The presented financial statements have been formulated with consideration of the company's ability to operate as a going concern. In light of this, the board of directors persists in utilizing the going concern concept for the preparation of the financial statements. At present, the company's existing resources and credit arrangements are deemed satisfactory to fulfill the immediate needs of its ongoing business activities.

Significant deviation from the last years operating result:

Significant variations over the last years operation of the company have been made due to excess expenditure incurred in the administrative and general expenses ,selling and distribution expenses and reduce expenditure incurred in the factory overhead .The positive impact of excess and reduce expenditure is gradually taking place.

Declaration of dividend:

The Board of directors is pleased to recommend a cash dividend @ 10% only for shareholders except sponsors or directors for financial year 2022-2023 based on the performance of the company. The recommend dividend is stated below:

Name of Shareholders	No of Share	Dividend-BDT	Remarks
Directors and Sponsors	1,42,50,000	Nil	
General shareholders	61,50,000	61,50,000	
Total	2,04,00,000	61,50,000	

Directors:

The name of Directors of the Company and their positions are shown on the following table:

Name of Directors	Position
Md. Billal Hossain	Chairman
Mohammad Zakir Hossain Patowary	Managing Director
Md. Kamrul Alam	Director

Re-election of Directors:

Mr.Md Kamrul Alam retires under Article 57 of the article of Association of the Company. Mr. Md. kamrul Alam eligible and offered himself for re-election. The board recommends his re-appointment.

Appointment of Statutory Auditors:

The Audit of the company for the year ended 30 June 2023 has been carried by the Auditors of the company Anil Salam Idris & Co. Chartered Accountants. The existing auditor is eligible for re-appointment. According the board of directors has recommended to re-appointment of Anil Salam Idris & Co. Chartered Accountants. Audit fees will be determined as per ICAB Guideline.

Pattern of Shareholders:

Name	Designation	% of Shares		No. of Share	
		30-06-2023	30-06-2022	30-06-2023	30-06-2022
Directors					
MD. Billal Hossain	Chairman	20.96%	27.76%	4,275,000	4,275,000
MD. Zakir Hossain Patwary	Managing Director	31.43%	41.64%	6,412,500	6,412,500
MD. Kamrul Alam	Director	17.46%	23.13%	3,562,500	3,562,500
Total		69.85%	92.53%	14,250,000	14,250,000
Others					
Foreign investors		-	-	-	-
Institutions		0.49%	0.00%	99,960	-
General shareholders		29.66%	7.47%	6,050,040	1150000
		30.15%	7.47%	6,150,000	1,150,000
		100.0%	100.0%	20,400,000	15,400,000

Dividend Policy:

- The profit of the Company, subject to any special right relating thereto created or authorized to be created by the Memorandum and subject to the provisions of the Articles of Association, shall be divisible among the members in proportion to the amount of capital paid-up on the shares held by them respectively.
- The dividend shall be recommended by the Board of Directors time to time for distributing the accumulated profit.
- No dividend shall be payable except out of the profits of the Company or any other undistributed profits. The dividend shall not carry interest as against the Company.
- The Directors may from time to time pay the members such interim dividend as in their judgment the financial position of the Company may justify.
- A transfer of shares shall not pass the right to any dividend declared thereon before the registration of transfer.
- The Company shall maintains all rules and compliance of DSE, CSE and BSEC on the subject of Dividend.
- No limitation in payment of the dividend is stipulated in any debt instrument or otherwise,

Legal and Other Information:

Sl.	Description of Certificate/ License/Registration	License Issuer/Issuing Authority
1	Certificate of Incorporation	Registrar of Joint Stock Companies & Firms, Bangladesh (RJSC)
2	Trade License	Gazipur City Corporation
3	TIN Certificate	National Board of Revenue Taxes Circle-161, Taxes Zone- 8, Dhaka
4	VAT Certificate	Custom, Excise and VAT Commissionarate, National Board of Revenue, Dhaka (North) Tangi Division

5	Import Registration Certificate (IRC)	Office of the Chief Controller of Imports and Exports
6	Export Registration Certificate (ERC)	Office of the Chief Controller of Imports and Exports
7	Fire Licence	Bangladesh Fire Service and Civil Defence, Dhaka
8	Environment Certificate- Veterinary Medicine (Formula)	Department of Environment, Gazipur
9	Certificate for Licence Manufacture Drugs	Directorate General of Drug Administration & Licencing Authorities (Drugs)
10	ISO Certification	QFS Management System LLP, India
11	Certificate of Good Manufacturing Practice (GMP) for Pharmaceutical Product(s)	Ministry of Health and Family Welfare
12	Export and Import Permit for Fisheries and Food Product	Department of Fisheries, Gazipur
13	Livestock Food Product Export, Import and Marketing (Category 2) License	Department of Livestock Services, Dhaka

Business Strategies:

- Utilizing the government support: The government usually tends to favor this industry. As a result, the government provides them with all of the assistance and support they require.
- Local market share: Competitors always try to increase their percentage of market share. So, Al-Madina Pharmaceuticals Limited will concentrate more to increase its market share.
- Inventory management system: Al-Madina Pharmaceuticals Limited will improve the existing inventory management system.
- Quality and control: Al-Madina Pharmaceuticals Limited will maintain the quality of its products in accordance with international standards.
- International market: Al-Madina Pharmaceuticals Limited will focus on international market to expand in the future.

SWOT Analysis:

SWOT analysis is the acronym for strength, weakness, opportunities, and threats which are a structured planning method that evaluates those four elements of a project or business venture.

Strength

- We provide high tech, high quality and affordable medicine
- Lowest-cost medicine producers
- Excellent transport system
- Strong chemistry, qualified employees, and process reengineering capabilities
- High ethical standards and rules in order to contribute meaningfully to people's well-being.
- Capability of inventing medicine benchmark
- Skilled workers
- Large customer Base
- Highly skilled sales forces & very efficient & wide distribution channels.
- Good reputation with a strong brand image.

Weakness

- Low investments in innovative R&D
- Allocation of resources such as human resource, financial resource, technical resource, physical resources and informational resources can be hard sometimes.
- Time-consuming decision-making process
- the loss of late introduction of new products
- Rapidly increasing costs of skilled manpower such as scientists, regulatory compliance personnel, pharmaceutical lawyers, international business development personnel are pushing up the cost of innovation.

Opportunities

- Bangladesh is currently producing life-saving international-standard drugs, and the country is on the verge of achieving pharmaceutical self-sufficiency.
- Bangladesh presently exports medications to roughly 30 nations, with plans to expand further next year.
- Intensive Government support.
- Invention of new products.
- Gaining market share from the existing rivals by offering new innovative product.
- This industry is often favored by the government. The laws and taxes are often in their favor.

Threats

- Due to the Existing Companies, Supply is exceeding demand creating prices to fall to a lower equilibrium price and a higher equilibrium quantity of goods and services.
- The pharmaceutical industry is becoming increasingly competitive. As a result, businesses must compete in the market with the innovative products offered by other companies
- Increasing the cost of labor, particularly basic wages, has an impact on the total cost of manufacturing and, as a result, on the selling prices of medications.

Qualitative Justification:

Some of the qualitative factors that help differentiate the Al-Madina Pharmaceuticals Limited from their competitors and enable them to compete successfully in the industry are as follows:

- The company has skilled and experienced management, field force and workers.
- The company equipped with modern machineries to manufacture pharmaceuticals products.
- The company has ensured product quality as International Standard.
- The company has strong research and development department.
- The company has proper strategic planning to develop business.
- The company has sophisticated fundamental marketing techniques.
- The company has strong distribution channels through which they can smoothly supply their products.
- Good corporate governance is prevailed in the company.

Management Appreciation:

The Board of Directors appreciate the contribution made and support and cooperation given by the officers, staff, workers, customers, creditors ,banks, insurance, utility providers, Bangladesh securities and exchange commission, Dhaka stock exchange and Chittagong stock exchange, central depository Bangladesh ltd and government in particular.

Thanks to all of you

On behalf of the board of directors



Md. Billal Hossain
Chairman.

**Independent Auditor’s Report to the Shareholders of
Al-Madina Pharmaceuticals Limited
Report on the Audit of the Financial Statements**

Opinion

We have audited the financial statements of Al-Madina Pharmaceuticals Limited (the Company), which comprise the statement of financial position as at 30 June 2023 and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Company as at 30 June 2023 and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditors’ Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants’ Code of Ethics for Professional Accountants (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statements in Bangladesh, and we have fulfilled our other ethical responsibilities in accordance with the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole and in forming our opinion thereon and we do not provide a separate opinion on these matters.

Key audit matter description	How the scope of our audit responded to the key audit matter
Revenue	Audit procedures performed
ISAs require that, as part of our overall response to the risk of fraud, when identifying and assessing the risks of material misstatement due to fraud, we evaluate which types of revenue or revenue transactions might give rise to potential fraud risks.	We performed walkthroughs of the revenue cycle at significant components to gain an understanding of when the revenue should be recognized, to map out the relevant controls end to end and the processes in place. We assessed the design and implementation of these controls. We tested a sample of individual sales transactions and traced to dispatch notes and subsequent cash receipt or other supporting documents.

Key audit matter description	How the scope of our audit responded to the key audit matter
The Company sells different kinds of pharmaceuticals products across all geographical areas in Bangladesh. We have specifically focused this key audit matter to cut-off and occurrence for revenue recorded within 30 June 2023. Pressures to meet stakeholders’ expectations could provide incentives to record revenues	We identified and considered the impact of any credit notes or inventory returns occurring after year-end, including evaluating the impact of any material overdue debts from customers.

<p>where controls of the goods have not passed.</p> <p>The associated disclosure is included within Note 21. For specific detail on the Company's accounting policy, please see Note 3.01.</p>	<p>With regard to the implementation of IFRS 15 "Revenue from Contract with Customers", we verified management's conclusion from assessing different types of contracts and the accuracy of the revised accounting policies in light of the industry specific circumstances and our understanding of the business. We tested the appropriateness of the accounting treatment on a sample basis. In addition, we verified the accuracy of IFRS 15 related disclosures.</p> <p>Key observations communicated to the Audit Committee</p> <p>We were satisfied that the revenue recognition policies have been applied appropriately. Based on the work performed, we concluded that revenue has been recorded appropriately.</p>
Inventory	
<p>At the reporting date, the carrying value of inventory amounted to Taka 26,313,770 which is 4.11% of total assets. Inventories were considered as a key audit matter due to the size of the balance and because inventory valuation involves management judgement.</p> <p>Inventory valuation and existence was an audit focus area because of the number of locations/stores that inventory was held at, and the judgement applied in the valuation of inventory to incorporate inventory shrinkage.</p> <p>According to the Company's accounting policy, inventories are measured at the lower of cost or net realizable value. The Company has specific procedures for identifying risk for obsolete items and measuring inventories at the lower of cost and net realizable value.</p> <p>The associated disclosure is included within Note 6. For specific detail on the Company's accounting policy, please see Note 3.04.</p>	<p>Audit procedures performed</p> <ul style="list-style-type: none"> • Assessing the compliance of Company's accounting policies over inventory with applicable accounting standards. • Assessing the inventory valuation process and practices. On major locations, we tested the effectiveness of the key controls. • Assessing the analyses made by management with respect to slow moving and obsolete stock. • Attending inventory count on 30 June 2023 and reconciling the count results to the inventory listings to test the completeness of data. • Comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories. • Reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year. • Evaluating the correctness of the valuation of raw materials and packing material as per FIFO method. • Reviewing the calculation of standard labor hours and their regular comparison with actual labor hours of production; and reviewing the process of valuing work-in-progress.

Key audit matter description	How the scope of our audit responded to the key audit matter
	<p>Key observations communicated to the Audit Committee</p> <p>We were satisfied that the inventory recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that inventories have been recorded appropriately.</p>
Property, plant and equipment and capital work in progress	
<p>At the reporting date, the carrying value of the Company's property, plant and equipment amounted to Taka 299,895,672. The valuation of property, plant, and equipment was identified as a key audit matter due to the significance of this balance to the financial statements, as well as the significance of management's judgements in determining its valuation.</p> <p>In considering the valuation of property, plant, and equipment, we focused on the assessment of the followings:</p> <ul style="list-style-type: none"> • Inherent risks associated with property, plant and equipment. • Potential misstatements in property, plant, and equipment on account of frauds and errors. • Assessment of useful lives of assets. • Assessment of impairment of assets. <p>Inherent risks associated with property, plant and equipment</p> <ul style="list-style-type: none"> • Property, plant and equipment may include assets that should have been derecognised following sale, other transfer of rights or abandonment. • Expenditure that should have been recognised as property, plant and equipment but has not been so recognised, including capitalised finance costs. • Depreciation may have been incorrectly calculated. Potential misstatements in property, plant, and equipment on account of frauds and errors <p>Potential misstatements in property, plant, and equipment on account of frauds and errors</p> <ul style="list-style-type: none"> • Purchase of an asset at an inflated price especially from a related party. 	<p>Audit procedures performed</p> <ul style="list-style-type: none"> • We obtained an understanding of the client and its environment to consider inherent risk related to property, plant, and equipment. Our understanding includes: <ul style="list-style-type: none"> ➢ Obtaining an understanding of the internal control over property, plant, and equipment. ➢ Assessing the risks of material misstatement and designing tests of controls and substantive procedures that cover the following aspects: <ul style="list-style-type: none"> ✓ Substantiate the existence of property, plant, and equipment. ✓ Establish the completeness of recorded property, plant, and equipment. ✓ Verify the cut-off of transactions affecting property, plant, and equipment. ✓ Establish the proper valuation or allocation of property, plant, and equipment and the accuracy of transactions affecting property, plant, and equipment. ✓ Determine the correctness and appropriateness of classification of property, plant and equipment. • We obtained an understanding of the potential misstatements in property, plant, and equipment on account of frauds and errors. • We evaluated the assumptions made by management in the determination of useful lives to ensure that these are consistent with the principles of IAS 16. "Property, Plant and Equipment". • We compared the useful lives of each class of asset in the current year to the prior year to determine whether there were any significant changes in the useful lives of assets, and considered the reasonableness of changes based on our knowledge of the business and the industry.

Key audit matter description	How the scope of our audit responded to the key audit matter
<ul style="list-style-type: none"> • Wrong write-off of the asset as scrap, obsolescence, missing, donated, or destroyed. • Expenditures for repairs and maintenance recorded as property, plant and equipment or vice versa. • Capitalization of expenditure which are not normally attributable to the cost of the property, plant and equipment. • Recording of an asset purchased, which in effect has not actually been received by the entity at all. <p>Valuation of capital work in progress to PPE Management needs to ensure that the assets under construction or pending installation and not yet ready for intended use are classified as work in progress. An appropriate system needs to put in place to capture all directly identifiable costs, which can be capitalised, to be so accumulated to capital work in progress whilst expenses which are not eligible for being capitalised are identified and charged to revenue in the normal course.</p> <p>Assessment of useful lives of assets Management applies estimates and judgements in its determination of useful lives of assets and reviews the useful lives of assets at each financial year end and adjusts for changes, where appropriate.</p> <p>Impairment of assets At the end of each reporting period, management assesses whether there is any indication that an asset may be impaired. If any such indication exists, management estimates the recoverable amount of the asset. If the recoverable amount of an asset is less than its carrying amount, the carrying amount of the asset is reduced to its recoverable amount.</p> <p>The associated disclosure is included within Note 4. For specific detail on the Company's accounting policy, please see Note 3.02.</p>	<ul style="list-style-type: none"> • We verified records e.g. contractor bills, work orders and certification of work performed by the specialized personnel to ensure that the assets under construction or pending installation and not yet ready for intended use are classified as work in progress. • We also verified the date on which the assets are moved from the capital work in progress account to the property, plant and equipment (the date on which the asset is ready for intended use), so that the depreciation on property, plant and equipment may be computed correctly. • We reconciled the movement of capital work in progress from opening to closing, specifically verifying additions during the year, capital assets completed during the year and impairment of any opening capital work in progress items. • We assessed whether there are circumstances that indicate a possible impairment of property, plant and equipment and if such circumstances exist, how the same have been dealt with by the entity. <p>Key observations communicated to the Audit Committee We were satisfied that the property, plant and equipment recognition and measurement policies have been applied appropriately. Based on the work performed, we concluded that property, plant and equipment have been recorded appropriately.</p>

Reporting on Other Information

Management is responsible for the other information. The other information comprises the information included in the Annual Report, other than the financial statements and our auditors' report thereon.

Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If we identify such material inconsistencies or apparent material misstatement, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in respect of these matters.

Responsibilities of Management and Those Charged with Governance for the Financial Statements and Internal Controls

Management is responsible for the preparation and fair presentation of the financial statements in accordance with IFRSs, the Companies Act 1994, the Securities and Exchange Rules 1987 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgement and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Company to express an opinion on the financial statements. We are responsible for the direction, supervision and performance of the company audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.


Report on other Legal and Regulatory Requirements

In accordance with the Companies Act 1994 and the Securities and Exchange Rules 1987 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report the following:

- a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit and made due verification thereof;
- b) in our opinion, proper books of accounts as required by law have been kept by the Company so far as it + appeared from our examination of these books;
- c) the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of accounts; and
- d) the expenditure incurred was for the purposes of the Company's business.

Firm's Name : Anil Salam Idris & Co., Chartered Accountants

Firm's Registration Number : P-50874/2023

Signature : 

Engagement Partner Name : Md. Anwar Hossain, FCA
Managing Partner/ Enrollment No. 1415

DVC Number : 2310111415AS610561

Date : 09 October 2023

Al-Madina Pharmaceuticals Ltd
Statement of Financial Position
As at 30 June 2023

	Notes	Amount in Taka	
		30 June 2023	30 June 2022
Assets			
Non-Current Assets			
Property Plant and Equipment	4.00	299,895,672	317,322,205
Work in Progress		3,020,900	-
Right-of-Use Asset (ROU)	5.00	14,259,760	15,844,178
		317,176,332	333,166,382
Current Assets			
Inventories	6.00	26,313,770	24,411,720
Inventories in Transit	7.00	3,277,085	3,133,256
Trade Receivables	8.00	214,863,981	144,589,522
Advance Deposit and Pre-Payments	9.00	36,030,322	25,345,244
Cash and Cash Equivalents	10.00	42,215,736	16,621,348
		322,700,893	214,101,090
Total Assets		639,877,225	547,267,472
Shareholder's Equity And Liabilities			
Equity			
Share Capital	11.00	204,000,000	154,000,000
Retained Earnings	12.00	61,301,946	40,433,725
Revaluation Reserve	13.00	138,967,050	138,967,050
		404,268,996	333,400,775
Non-Current Liabilities			
Deferred Tax Liabilities	14.00	8,787,596	3,404,293
Long Term Loan	15.01	4,564,509	7,874,546
Lease Obligation	16.03	2,237,886	3,978,700
		15,589,991	15,257,539
Current Liabilities & Provisions			
Long Term Loan (Current portion)	15.01	3,310,037	1,284,461
Lease Obligation (Current portion)	16.03	1,866,003	3,671,146
Short Term Loan	17.00	163,348,334	148,909,450
Accounts Payable	18.00	3,840,445	3,145,000
Liabilities for Expenses	19.00	21,911,378	21,754,562
Provision for income tax	20.00	25,742,043	19,844,540
		220,018,240	198,609,159
Total Shareholders' Equity And Liabilities		639,877,225	547,267,472
Net Asset Value Per Share (NAVPS) with revaluation	28.00	19.82	21.65
Net Asset Value Per Share (NAVPS) without revaluation	29.00	13.00	12.63

The annexed notes are an integral part of these financial statements.


Company Secretary


Chief Financial Officer



Managing Director


Chairman

Signed in terms of our report of even date annexed.

Dated: Dhaka
09 October 2023

Anil Salam Idris & Co.
Chartered Accountants
Firm's Registration No. P-50874/2023


Md. Anwar Hossain, FCA
Managing Partner
Enrollment No: 1415
DVC No: 2310111415AS610561

Al-Madina Pharmaceuticals Ltd
Statement of Profit or Loss and other Comprehensive Income
For the year ended 30 June 2023

	Notes	Amount in Taka	
		01 July 2022 to 30 June 2023	01 July 2021 to 30 June 2022
Sales Revenue	21.00	685,624,856	668,965,108
Less: Cost of Goods Sold	22.00	404,897,888	400,703,383
Gross Profit		280,726,968	268,261,725
Less: Administrative & General Expenses	23.00	32,783,093	31,060,010
Less: Marketing, Selling & Distribution Expenses	24.00	199,671,749	190,999,957
Operating Profit		48,272,126	46,201,758
Less: Financial Expenses	25.00	14,515,647	12,321,155
Net Profit / (Loss) for the year before WPPF		33,756,479	33,880,603
Less: Workers' Profits Participation Funds		1,607,451	1,613,362
Net Profit / (Loss) before Tax		32,149,027	32,267,241
Income Tax Expenses			
Less: Current tax	26.00	5,897,504	9,680,172
Deferred Tax Expenses	26.00	1,085,353	2,848,529
Net profit after tax for the year		25,166,171	19,738,540
Other Comprehensive Income:		-	-
Total Comprehensive Income for the year		25,166,171	19,738,540
Earning Per Share (EPS)	27.00	1.57	1.30

The annexed notes are an integral part of these financial statements.


Company Secretary


Chief Financial Officer


Managing Director


Chairman

Signed in terms of our report of even date annexed.

Dated: Dhaka
09 October 2023

Anil Salam Idris & Co.
Chartered Accountants
Firm's Registration No. P-50874/2023


Md. Anwar Hossain, FCA
Managing Partner
Enrollment No: 1415
DVC No: 2310111415AS610561

Al-Madina Pharmaceuticals Ltd
Statement of Changes in Shareholder's Equity
For the year ended 30 June 2023

Particulars	Amount in BDT			
	Share Capital	Retained Earnings	Revaluation Reserve	Total
Balance as at 1 July 2022	154,000,000	40,433,725	138,967,050	333,400,775
Share issue during year	50,000,000	-	-	50,000,000
Prior Year Adjustment (deferred tax)	-	(4,297,950)	-	(4,297,950)
Profit / (Loss) for the Year	-	25,166,171	-	25,166,171
Balance as at 30 June 2023	204,000,000	61,301,946	138,967,050	404,268,996

For the year ended 30 June 2022

Particulars	Amount in BDT			
	Share Capital	Retained Earnings	Revaluation Reserve	Total
Balance as at 1 July 2021	128,000,000	20,695,185	138,967,050	287,662,235
Share issue during year	26,000,000	-	-	26,000,000
Profit /Loss for the year	-	19,738,540	-	19,738,540
Balance as at 30 June 2022	154,000,000	40,433,725	138,967,050	333,400,775


Company Secretary


Chief Financial Officer


Managing Director


Chairman

Dated: Dhaka
09 October 2023

Al-Madina Pharmaceuticals Ltd
Statement of Cash Flows
For the year ended 30 June 2023

	Notes	Amount in Taka	
		01 July 2022 to 30 June 2023	01 July 2021 to 30 June 2022
A. Cash Flows from Operating Activities:			
Cash Received from Customer		615,350,397	678,556,692
Cash Paid to Suppliers, Employees and Other Expenses		(632,629,033)	(680,743,955)
Tax Paid		(9,044,626)	(6,214,341)
Net Cash Generated from Operating Activities	31.00	(26,323,262)	(8,401,604)
B. Cash Flows from Investing Activities:			
Acquisition of Property, Plant and Equipment		(2,690,815)	(24,516,710)
Payment against Construction Work in Progress		(5,000,000)	-
Net Cash Flows from/(Used In) Investing Activities		(7,690,815)	(24,516,710)
C. Cash Flows from Financing Activities:			
Proceed/Repayment of Long Term Loan from Bank		(1,284,461)	2,347,516
Issuing of Share Capital		50,000,000	26,000,000
Proceed/Repayment of Lease Rent		(3,545,957)	(7,387,227)
Proceed/Repayment of Short Term Loan		14,438,884	16,581,662
Net Cash Flows from Financing Activities		59,608,466	37,541,952
D. Increase/(Decrease) in Cash And Cash Equivalents (A+B+C)		25,594,389	4,623,638
E. Cash and Cash Equivalents at the Beginning of the Year		16,621,348	11,997,710
F. Cash and Cash Equivalents at the End of the Year (D+E)	10.00	42,215,736	16,621,348
Net Operating Cash Flow Per Share (NOCFPS)	30.00	(1.64)	(0.55)


Company Secretary


Chief Financial Officer


Managing Director


Chairman

Dated: Dhaka
09 October 2023

Al-Madina Pharmaceuticals Ltd
Notes to the Financial Statements
As at and for the year ended 30 June 2023

1.00 Reporting entity

1.01 About the company

Al-Madina Pharmaceuticals Limited was established as a private limited company in Bangladesh on July 27, 2006, in accordance with the Companies Act of 1994, as evidenced by Certificate of Incorporation No. C-62976(467)/06. Its commercial operations officially began on October 21, 2007. On January 6, 2022, it transitioned into a public limited company. Furthermore, the company was listed on the Dhaka Stock Exchange Ltd. and Chittagong Stock Exchange Ltd. on May 22, 2023.

The address of the company are as follows:

Registered and Factory Office : 1/1, Tilargati, Kakil, Tongi-1711, Gazipur.

Corporate Head Office: 178-179, Farmgate, Tejturi Bazar Road, Road-23, Ward-39, Tejgaon, Dhaka.

1.02 Nature of the business

The Company is engaged in the manufacturing, buying, selling, refinement, import, export or otherwise of pharmaceuticals, medical and medicinal products, and preparations, patent drugs and proprietary articles of all kinds, whether basic or derived and in all forms. Al-Madina Pharmaceuticals Limited started its journey for veterinary drugs in 2007 and human drugs in 2019. At present, it is manufacturing veterinary drugs such as antibacterial drugs, nutritional products, poultry vaccines, aqua products, daily injectable products etc. and human drugs such as anti-bacterial drugs, anti-fungal drugs, gastro-intestinal drugs, analgesic & anti-inflammatory drugs, vitamins-minerals or supplements, drugs acting on urogenital system and drugs acting on respiratory system etc.

2.00 Basis of preparation of Financial Statements

2.01 Basis of measurement

The financial statements have been prepared based on the principle of a going concern, utilizing the historical cost convention as the primary framework. Additionally, certain land properties have been revalued and incorporated into the reporting. The Company has consistently applied these accounting policies, unless explicitly indicated otherwise, maintaining alignment with previous years' practices.

2.02 Statement of compliance

The financial statements have been meticulously prepared to adhere to the stipulations set forth by the Companies Act of 1994, the Securities and Exchange Rules of 2020, The Value Added Tax and Supplementary Duty Act, 2012, the Income Tax Act 2023 and pertinent local regulations. Furthermore, these statements have been crafted in accordance with the guidelines of the International Financial Reporting Standard (IFRS) and the International Accounting Standards (IAS).

2.03 Presentation of Financial Statements:

"The financial statements provided adhere to the guidelines outlined in IAS 1: Presentation of Financial Statements.

These financial statements consist of the following components:

- (a) Statement of Financial Position as of June 30, 2023
- (b) Statement of Profit or Loss and Other Comprehensive Income for the period from July 1, 2022, to June 30, 2023
- (c) Statement of Changes in Shareholders' Equity for the period from July 1, 2022, to June 30, 2023
- (d) Statement of Cash Flows for the period from July 1, 2022, to June 30, 2023
- (e) Statement of Notes, which includes a summary of significant accounting policies and explanatory information."

2.04 Reporting Period

The financial statements cover a year from July 01, 2022 to June 30, 2023

2.05 Authorization for issue

The financial statements were approved by the Board of Directors and authorized for issue on 09 October 2023

2.06 Functional and Presentation Currency

The financial statements are prepared and presented in Bangladesh Taka (Taka/BDT), which is the Company's functional currency.

2.07 Use of Estimates and Judgments

Preparation of financial statements in accordance with IFRSs and IASs necessitates managerial assessments, projections, and assumptions that impact the implementation of accounting policies and the presentation of asset, liability, income, and expense figures, as well as disclosures regarding contingent assets and liabilities, both during the reporting period and at the statement date.

Discrepancies between these projections and actual outcomes are possible. The assessments and underlying presumptions are regularly evaluated. Any modifications to accounting assessments are recognized in the reporting period in which they are altered and in any subsequent periods affected.

"Notably, the key areas of estimation, inherent uncertainty, and pivotal judgments in the application of accounting policies that exert the most substantial influence on the figures acknowledged in the financial statements encompass aspects like depreciation, inventory assessment, accrued liabilities, and other payables."

2.08 Business Risk

Adhering to IFRS 7: Financial Instruments, the financial statement has been formulated with consideration of credit risk, liquidity risk, and market risk.

Credit Risk: The Company operates under a credit policy that guides credit issuance. Security measures, such as obtaining blank cheques from customers and counterparties, are implemented during credit sales, minimizing credit risk exposure.

Liquidity Risk: Liquidity risk arises from financial obligations. The Company's sales team is dedicated to adhering to a systematic collection plan for sales proceeds. As a result, the Company's liquidity risk is kept at a minimum.

Market Risk: Market risk hinges on factors like raw material supply, political stability, and environmental conditions. The Company has a well-defined strategy in place to mitigate potential market risks.

2.09 Going Concern

The presented financial statements have been formulated with consideration of the company's ability to operate as a going concern. The company possesses ample resources to sustain its operations in the foreseeable future. In light of this, the board of directors persists in utilizing the going concern premise for the preparation of the financial statements. At present, the company's existing resources and credit arrangements are deemed satisfactory to fulfill the immediate needs of its ongoing business activities.

2.10 Statement of cash flows

The statement of cash flows has been crafted in adherence to the guidelines outlined in IAS 7, "Statement of Cash Flows," employing the direct method. Additionally, a reconciliation of Net Operating Cash Flow stemming from operating activities has been generated, encompassing the indirect method.

3.00 Significant Accounting Policies

The accounting principles and policies pertaining to significant components of the financial statements, as detailed below, have been consistently employed across all periods presented within these financial statements.

3.01 Revenue Recognition

In alignment with the stipulations outlined in IFRS 15, "Revenue," revenue receipts stemming from customer transactions related to sales are acknowledged at the point when products are dispatched to customers. This is contingent upon the pivotal moment when the substantial risks and rewards associated with ownership have been transferred to the purchaser. Moreover, recognition takes place when the recovery of consideration is deemed likely, the related costs and potential product returns can be reasonably estimated, and there exists no ongoing managerial involvement with the merchandise.

3.02 Property, Plant and Equipment

(a) Recognition and Measurement

In conformity with the stipulations outlined in IAS 16, "Property, Plant and Equipment," the presentation of these items has been carried out either at their historical cost or revalued amount, less the accumulated depreciation. The cost of acquiring an asset encompasses its initial purchase price and any costs directly linked to rendering the asset operational for its intended purpose. This incorporates expenses such as inbound freight, duties, and non-refundable taxes.

(b) Maintenance Activities

The company bears maintenance expenses for its significant property, plant, and equipment assets. Costs associated with repairs and maintenance are expensed as they are accrued.

(c) Depreciation

Depreciation is allocated to systematically distribute the cost of assets post-commissioning over the duration of their anticipated useful lives, following the guidelines set forth in IAS 16, "Property, Plant and Equipment." The method employed for this purpose is the reducing balance basis.

Category of Fixed Assets for Depreciation	Depreciation Rate
Land and land development	-
Factory building and Construction	5.00%
Plant and Machinery	15.00%
Generator	15.00%
Air conditioner	15.00%
Water pump	15.00%
Gas line cost	15.00%
Furniture & fixture	20.00%
Office decoration/Equipment	15.00%
Television	15.00%
Fridge	15.00%
Electric fittings	15.00%
Motor cycle	15.00%
Computer	20.00%
Computer printer	15.00%
Photocopy machine	10.00%
Right-of-use - Covered Van	10.00%
Right-of-use - Motor Bike	10.00%

3.03 Right of Use Assets

"The company identifying a contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. Control is conveyed where the customer has both the right to direct the identified asset's use and to obtain substantially all the economic benefits from that use.

The right of use asset is initially measured at the amount of the lease liability plus any initial direct costs incurred by the lessee. Adjustments may also be required for lease incentives, payments at or prior to commencement and restoration obligations or similar.

Depreciation have charged on right to use assets on reducing balance method over the lease period.

The lease liability is initially measured at the present value of the lease payments payable over the lease term, discounted at the rate implicit in the lease if that can be readily determined. If that rate cannot be readily determined, the lessee shall use their incremental borrowing rate.

3.04 Inventories

In accordance with IAS 2, "Inventories," inventory items are recognized at the lower of their cost or net realizable value. The determination of cost follows the weighted average cost methodology. The cost of inventories encompasses expenditures incurred during routine business operations to bring the inventories to their existing state and location. Net realizable value is calculated based on the projected selling price, minus any additional expenses anticipated for the completion of the sale.

3.05 Trade Receivable

"Trade receivables are initially recorded at their invoice value, with an adjustment for estimated Expected Credit Losses (ECL). The determination to label a debt as uncollectible occurs when there is credible evidence of potential non-payment. This evaluation takes into account factors such as the aging of the debt, historical payment patterns, and the prevailing economic conditions. When a trade receivable is deemed irrecoverable, it is promptly written off and recognized as an expense in the profit and loss account. Any subsequent recoveries of previously written-off amounts are recorded as income in the profit and loss account.

It's important to note that management views bills receivable for the current year as both financially sound. The company computes the Expected Credit Loss (ECL) for each stage using the relevant inputs and subsequently acknowledges an allowance in its financial statements. This allowance lowers the recorded value of the receivables, and any subsequent modifications to this allowance are recorded as either expenses or income in the income statement.

3.06 Cash and Cash Equivalents

The category of cash and cash equivalents encompasses both physical cash on hand and funds held in bank accounts, spanning both current and deposit accounts. These funds are readily accessible to the company for utilization without any constraints. The likelihood of a substantial alteration in their value is minimal.

3.07 Income Taxes:**Current Tax**

"A provision for income tax has been established in adherence to the stipulations outlined in the Income Tax Act and associated regulations."

Deferred Tax

Deferred income tax is recognized for all transient timing disparities that emerge between the tax base of assets and liabilities and their recorded values within the financial statements, conforming to the guidelines set forth in IAS 12, "Income Taxes." The tax rate prevailing as of the balance sheet date is employed to ascertain deferred income tax.

3.08 Status of Income Tax Assessment

The status of income tax assessment shown in details as under:

Income year	Assessment Year	Assessment completed under ITO 1984
2019-2020	2020-2021	Submitted under Section 82BB
2020-2021	2021-2022	Submitted
2021-2022	2022-2023	Submitted

3.09 VAT (Value Added Tax):

The Company submitted the required return as per Value Added Tax and Supplementary Duty Act 2012.

3.10 Employees Benefit Plans

Workers Profit Participation Fund and Welfare Fund

The company routinely designates 5% of the net profit before tax to this fund, as dictated by the stipulations outlined in the Bangladesh Labour Law 2006, amended up to 2013.

3.11 Provisions

A provision is documented within the statement of financial position when the company possesses a legal or implicit obligation stemming from a prior event. This obligation is anticipated to necessitate an outflow of economic resources, and a dependable estimate can be established for the obligation's value. Provisions are generally assessed at the most accurate projection of the outlay necessary to settle the current obligation at the date of the statement of financial position. In cases where the influence of the time value of money holds significance, the provision amount is computed at the present value of the anticipated expenses essential to satisfy the obligation.

3.12 Interest Income and Borrowing Cost

interest income is acknowledged based on the accrual principle. On the other hand, borrowing costs are documented as expenses within the time frame in which they are accrued, unless the possibility of capitalization is authorized in accordance with IAS 23, "Borrowing Costs."

3.13 Operating segments

Since the company operates within a single business and geographic segment, there is no need for segment reporting as there are no distinct operating segments to report on.

3.14 Events after the reporting period

Events occurring after the reporting period encompass both positive and negative developments that take place between the end of the reporting period and the date when the financial statements are approved for issuance. These events can be categorized into two distinct types: adjusting events, which offer evidence of conditions that were in existence at the conclusion of the reporting period, and non-adjusting events, which signal conditions that emerged after the reporting period concluded. Please refer to Note 33 in the financial statements for further details regarding these events.

3.15 Earnings Per Share (EPS)

This computation adheres to the specifications set forth in IAS 33, "Earnings Per Share," achieved by dividing basic earnings by the weighted average count of ordinary shares outstanding throughout the year.

3.16 Capital commitment

There is no capital commitment at statement of financial position date.

3.17 The following IAS/IFRS are applicable for the preparation of financial statements for the period under review:

Name of the IAS	IAS No	Status
Presentation of Financial Statements	1	Applied
Inventories	2	Applied
Statement of Cash Flows	7	Applied
Accounting Policies, Changes in Accounting Estimates and Errors	8	Applied
Events after the Reporting Period	10	Applied
Income Taxes	12	Applied
Property, Plant and Equipment	16	Applied
Employee Benefits	19	Applied
Accounting for Government Grants and Disclosure of Government Assistance	20	N/A
The Effects of Changes in Foreign Exchange Rates	21	Applied
Borrowing Costs	23	Applied
Related Party Disclosures	24	Applied
Accounting and Reporting by Retirement Benefit Plans	26	N/A
Consolidated and Separate Financial Statements	27	N/A
Investment in Associates and Joint Ventures	28	Applied
Interest in Joint Ventures	31	N/A
Financial Instruments: Presentation	32	Applied
Earnings Per Share	33	Applied
Interim Financial Reporting	34	N/A
Impairment of Assets	36	Applied
Name of the IFRS	IFRS No	Status
Provision, Contingent Liabilities and Contingent Assets	37	Applied
Intangible Assets	38	N/A
Financial Instruments: Recognition and Measurement	39	N/A
Investment Property	40	N/A
Agriculture	41	N/A
First Time Adaption of IFRS	1	N/A
Share Based Payment	2	N/A
Business Combinations	3	N/A
Insurance Contracts	4	N/A
Non-current Assets Held for Sale and Discontinued Operations	5	N/A
Exploration for and Evaluation of Mineral Resources	6	N/A
Financial Instruments: Disclosure	7	N/A
Operating Segments	8	Applied
Financial Instruments	9	N/A
Consolidated Financial Statements	10	N/A
Joint Arrangements	11	N/A
Disclosure of Interest in other Entities	12	N/A
Fair Value Measurement	13	Applied
Regulatory Deferral Accounts	14	N/A
Revenue from Contracts with Customers	15	Applied
Leases	16	Applied
Insurance Contracts	17	N/A

3.18 Rearrangement and Reclassification for Comparative Analysis

For the sake of comparison, the financial statements of the previous year have been adjusted by rearranging and reclassifying the figures and account titles as required. This modification has been carried out without introducing any alteration to the reported profit, assets, and liabilities values in the financial statements of both the current and preceding years.

		Amount in Taka	
		30 June 2023	30 June 2022
4.00 Property, Plant And Equipment			
A Cost:			
Opening Balance		395,388,742	370,872,032
Add: Addition during the year		2,690,815	24,516,710
Closing Balance		398,079,557	395,388,742
B Accumulated Depreciation			
Opening Balance		78,066,537	55,424,962
Add: Depreciation charged during the year		20,117,348	22,641,575
Closing Balance		98,183,885	78,066,537
C Written Down Value (A-B)			
		299,895,672	317,322,205
Property, Plant And Equipment is given in details in Schedule-I			
5.00 Right-of-Use Asset (ROU)			
A Cost			
Opening Balance		20,750,242	15,728,000
Add: Additions made during the year		-	5,022,242
Closing Balance		20,750,242	20,750,242
B Accumulated Depreciation			
Opening Balance		4,906,064	3,145,600
Add: Deprecation Charged during the year		1,584,418	1,760,464
Closing Balance		6,490,482	4,906,064
C Written Down Value (A-B)			
		14,259,760	15,844,178
Right-of-Use Asset is given in details in Schedule -I			
6.00 Inventories			
Raw Material		9,012,450	8,015,420
Packing Materials		2,749,320	2,145,100
Finished Goods		14,552,000	14,251,200
		26,313,770	24,411,720
7.00 Inventories In Transit			
Raw Material (Import)		3,277,085	3,133,256
		3,277,085	3,133,256
8.00 Trade Receivable			
Trade receivables		215,943,699	145,281,543
Less: Allowance for Expected Credit Loss	8.01	1,079,718	692,021
		214,863,981	144,589,522
8.01 Allowance for Expected Credit Loss			
Opening Balance		692,021	125,102
Addition during the year		387,697	692,021
Written off during the year		-	125,102
Closing Balance		1,079,718	692,021

		Amount in Taka	
		30 June 2023	30 June 2022
9.00 Advance Deposits and Prepayments			
	Security Deposit (DESCO)	42,000	42,000
	Security Deposit (Gas Line)	237,300	237,300
	Security Deposit (Brac Poultry)	105,700	105,700
	Security Deposit CDBL	300,000	-
	Advance income tax	33,038,222	23,993,596
	Salary and others	-	966,648
	Advance for Local Machinery procurement	328,000	-
	Advance for Building Construction	1,979,100	-
		36,030,322	25,345,244
9.01 Advance Income Tax			
	Opening Balance	23,993,596	17,779,255
	Advance Tax Paid against Import During the Year	8,926,296	6,214,341
	Advance Tax Deducted During the Year	118,330	-
	Less: Adjustment during the year	-	-
		33,038,222	23,993,596
9.02 Advance for Building Construction			
	Opening Balance	-	-
	Addition during the year	5,000,000	-
	Less: Adjustment during the year	3,020,900	-
		1,979,100	-
10.00 Cash and Cash Equivalents			
	Cash in Hand	14,561,935	14,958,415
	Cash at Bank	27,653,801	1,662,933
		42,215,736	16,621,348
10.01 Cash in Hand			
	Cash in Head Office	13,851,435	14,410,397
	Cash in Factory	710,500	548,018
		14,561,935	14,958,415
10.02 Cash at Bank			
	Islami Bank Ltd., CA No.-280815	49,110	375,974
	Shahjalal Islami Bank Ltd. CA No. 00751	19,915	265,194
	Pubali Bank Ltd. A/C No-28873	7,201	426,565
	Pubali Bank Ltd. A/C No-8118	16,140	7,738
	IFIC Bank Ltd. A/C No-8041	3,465	205,854
	Al-Arafah Islami Bank Ltd. A/C-8113	17,362	70,147
	Dutch Bangla Bank Ltd A/C No-124169	118,434	275,710
	Dutch Bangla Bank Ltd A/C No-1027	228,681	35,751
	Shahjalal Islami Bank Ltd. CA No. 113	27,193,493	-
		27,653,801	1,662,933
11.00 Share Capital			
(i) Authorized:			
	30,000,000 Ordinary Shares of Taka 10/- each	300,000,000	300,000,000

Amount in Taka	
30 June 2023	30 June 2022

(ii) Issued, Subscribed & Paid up Capital:

a) By Cash:		
11,900,000 Ordinary Shares of Taka 10/- each fully paid-up in cash	119,000,000	69,000,000
(b) Other than Cash:		
8,500,000 Ordinary Shares of Taka 10/- each fully paid-up for consideration other than cash	85,000,000	85,000,000
	204,000,000	154,000,000

The above balance has been received from the following :

Name	Designation	% of Shares		No. of Shares	
		30-06-2023	30-06-2022	30-06-2023	30-06-2022
Directors					
MD. Billal Hossain	Chairman	20.96%	27.76%	4,275,000	4,275,000
MD. Zakir Hossain Patwary	Managing Director	31.43%	41.64%	6,412,500	6,412,500
MD. Kamrul Alam	Director	17.46%	23.13%	3,562,500	3,562,500
		69.85%	92.53%	14,250,000	14,250,000
Others					
Foreign investors		-	-	-	-
Institutions		0.49%	0.00%	99,960	-
General shareholders		29.66%	7.47%	6,050,040	1150000
		30.15%	7.47%	6,150,000	1,150,000
		100.0%	100.0%	20,400,000	15,400,000

12.00 Retained Earnings

Opening Balance	40,433,725	20,695,185
Prior Year Adjustment (Deferred Tax)	(4,297,950)	-
Net Profit/(Loss) for the year	25,166,171	19,738,540
Closing Balance	61,301,946	40,433,725

The rationale behind the adjustment for the prior year is elaborated upon in Note 14.

13.00 Revaluation Reserve

On June 30, 2021, Masih Muhith Haque & Co., Chartered Accountants, undertook the revaluation process. Initially, the Land and Land Development were valued at Tk 4,185,000. Following the revaluation, these assets were assessed at Tk 147,450,000, indicating a significant surge of Tk 143,265,000 in their worth. Additionally, a revaluation reserve was recognized, net of taxation adjustments.

Revaluation Reserve of Land and Land Development	138,967,050	138,967,050
	138,967,050	138,967,050

14.00 Deferred Tax Liabilities

Opening Balance	3,404,293	4,297,950
Add/(Less) Adjustment Deferred Tax Asset	-	3,742,186
Add: Prior year adjustment on revaluation reserve*	4,297,950	-
Add: Deferred tax expense/(Income) during the year Note-26.2	1,085,353	2,848,529
	8,787,596	3,404,293

Amount in Taka	
30 June 2023	30 June 2022

"*In the preceding fiscal year, an error transpired in which the deferred tax pertaining to the revaluation surplus was inaccurately offset against deferred tax assets, leading to an entry affecting the income statement. During the current fiscal year, we have taken corrective measures by appropriately reallocating this adjustment to deferred tax liabilities and retained earnings.

In line with the provisions of IAS 8 "Accounting Policies, Changes in Accounting Estimates and Errors," paragraph 42, entities are obligated to rectify material errors from prior periods through retrospective adjustments in the financial statements endorsed for issuance subsequent to their identification. Despite rectifying this in the current year's financial statement, the extent of this correction was determined to be immaterial. As a result, no revisions were made to the comparative figures."

15.00 Long Term Loan

Shahjalal Islami Bank Ltd

7,874,546	9,159,007
7,874,546	9,159,007

15.01 Long Term Loan

Non-Current Portion-Shahjalal Islami Bank Ltd

4,564,509

7874546

Current Portion-Shahjalal Islami Bank Ltd

3,310,037

1,284,461

7,874,546

9,159,007

16.00 Lease Obligation

Covered Van -Ifad Autos Ltd

16.01

244,935

2,169,824

Motor Bike-Shahjalal Islami Bank Ltd

16.02

3,858,954

5,480,022

4,103,889

7,649,846

16.01 Covered Van -Ifad Autos Ltd

Opening Balance

2,169,824

4,959,613

Addition during the year

-

2,800,000

Less: Payment during the year

1,924,889

5,589,789

244,935

2,169,824

16.02 Motor Bike-Shahjalal Islami Bank Ltd

Opening Balance

5,480,022

5,055,218

Addition during the year

2,222,242

Less: Payment during the year

1,621,068

1,797,438

3,858,954

5,480,022

16.03 Lease Obligation

Non-Current Portion-Ifad Autos Ltd

2,237,886

3,978,700

Current Portion-Shahjalal Islami Bank Ltd

1,866,003

3,671,146

4,103,889

7,649,846

17.00 Short Term Loan

Al-Arafah Islami Bank Ltd (Bai-Muazzal)

10,915,500

5,456,250

Al-Arafah Islami Bank Ltd (MPI-TR)

49,223,301

22,031,219

Shahjalal Islami Bank Ltd.(MPI-TR)

61,675,454

44,666,298

Shahjalal Islami Bank Ltd. (Bai Muazzal)

41,534,079

76,755,683

163,348,334

148,909,450

		Amount in Taka	
		30 June 2023	30 June 2022
18.00 Accounts Payable			
Accounts Payable		3,840,445	3,145,000
		3,840,445	3,145,000
19.00 Liabilities for Expenses			
Audit Fees		172,500	172,500
Salary & Wages		15,012,400	19,158,930
Electric Bill (Factory)		880,862	809,770
TDS Payable		159,325	-
VAT Payable		3,917,503	-
WPPF Payable	19.01	1,768,788	1,613,362
		21,911,378	21,754,562
19.01 WPPF Payable			
Employee welfare fund	19.01.01	160,745	161,336
Bangladesh workers welfare foundation	19.01.02	322,081	161,336
Workers profit participation fund	19.01.03	1,285,961	1,290,690
		1,768,788	1,613,362
19.01.01 Employee welfare fund			
Opening balance		161,336	216,221
Addition during the year		160,745	161,336
Payment during the year		161,336	216,221
		160,745	161,336
19.01.02 Bangladesh workers welfare foundation			
Opening balance		161,336	216,221
Addition during the year		160,745	161,336
Payment during the year		-	216,221
		322,081	161,336
19.01.03 Workers profit participation fund			
Opening balance		1,290,690	1,729,771
Addition during the year		1,285,961	1,290,690
Payment during the year		1,290,690	1,729,771
		1,285,961	1,290,690
20.00 Provision for Income Tax			
Opening Balance		19,844,540	10,164,367
Provision during this year		5,897,504	9,680,172
Less: Adjustment during the year		-	-
		25,742,043	19,844,540

Amount in Taka	
01 July 2022 to 30 June 2023	01 July 2021 to 30 June 2022

The company experienced a BDT 2,406,678 increase in the cost of goods sold for the fiscal year ending on June 30, 2022, primarily due to a reorganization in the utilization of Property, Plant, and Equipment and a reallocation of depreciation charges. This resulted in a 0.36% decrease in the gross profit margin.

23.00 Administrative & General Expenses

Salary & Allowance	21,881,000	21,676,914
Office Rent	600,000	600,000
Stationary	228,839	353,021
Entertainment	378,100	344,461
Audit Fees	172,500	172,500
Electricity bill	447,780	352,602
Donation/Gift	394,978	13,500
Conveyance Allowance	816,520	951,400
Bank charge	35,120	71,500
GAS Bill	5,597	13,597
Fuel	14,260	12,500
Product development Expenses	75,120	80,120
Water bill	39,571	90,781
Postage	26,081	37,393
Internet Bill	98,250	69,000
Newspaper & periodicals	340	7,200
Uniform	5,500	11,200
Medical Expenses	84,300	80,000
Misc. Expense	11,200	10,200
Maintenance	275,159	150,541
Depreciation Expenses	471,412	427,960
Telephone	7,845	29,916
Mobile bill	287,198	183,200
Labour Bill	5,530	32,660
Food Allowance	503,671	727,594
Product Registration and Others Fee	415,150	554,250
Attendance Fee of Board meeting	54,000	54,000
Director Remuneration	3,900,000	3,900,000
Credit Rating Fees	37,372	27,000
Listing Fee and Exp.	624,800	25,000
Issue Expenses	885,900	-
	32,783,093	31,060,010

24.00 Marketing, Selling and Distribution Expenses

Salary & Allowance	178,699,350	169,941,947
Depot Rent	158,500	372,400
Stationery	563,241	940,572
Entertainment	340,028	395,377
Electricity bill	103,380	188,944
Donation	155,457	211,565
Conveyance Allowance	9,825,000	7,240,000
Bank charges	32,389	126,450
GAS Bill	46,769	219,500

	Amount in Taka	
	01 July 2022 to 30 June 2023	01 July 2021 to 30 June 2022
GAS Bill	46,769	219,500
Fuel	3,978,633	3,609,988
Product development Expenses	14,250	16,100
Water bill	42,898	26,357
Postage	145,800	68,835
Internet Bill	74,872	138,203
Newspaper & periodicals	3,500	12,400
Free sample	1,945,000	2,160,043
Uniform	71,500	121,450
Medical Expenses	28,000	280,120
Miscellaneous Expenses	25,410	42,510
Maintenance	152,025	196,156
Business Promotional Expenses	541,500	581,998
Depreciation Expenses	1,662,986	2,045,770
Mobile bill	401,200	431,856
Loading /Unloading Expenses	233,641	876,145
Expected Credit Loss Expense	387,697	692,021
License renewal	38,723	63,250
	199,671,749	190,999,957
25.00 Financial Expenses		
Interest Expenses	14,515,647	12,321,155
	14,515,647	12,321,155
26.00 Income Tax Expenses		
Current Tax	5,897,504	9,680,172
Deferred Tax expenses/(Income)	1,085,353	2,848,529
	6,982,856	12,528,701
26.01 Current Tax Calculation		
Profit from operation before tax	32,149,027	32,267,241
Sub total	32,149,027	32,267,241
Add: Inadmissible Expenses		
Accounting Depreciation for separate consideration	20,117,348	24,402,039
Lease - Depreciation	1,584,418	-
Lease - Interest expenses	415,933	-
Expected Credit Loss Expense	387,697	-
Total	54,654,423	56,669,280
Less: Admissible Expenses		
Lease Payment	3,545,957	7,387,227
Depreciation as per 3rd Schedule of ITO-1984	24,897,338	29,986,013
Total Taxable Income from Business	26,211,128	19,296,040
	Applicable tax rate applied	Applicable tax rate applied
Tax Rate	5,897,504	9,680,172
A) Income Tax		
B) Minimum Tax:		
From Turnover:	Turnover (Taka)	Minimum tax (Taka)
Turnover @ 0.6%	685,624,856	4,113,749
		4,113,749
Current Tax (whichever is higher between A & B)	5,897,504	9,680,172

Amount in Taka	
01 July 2022 to 30 June 2023	01 July 2021 to 30 June 2022

31.00 Reconciliation of net profit with cash flows from operating activities

Net profit after tax	25,166,171	19,738,540
Depreciation	21,701,766	24,402,039
(Increase)/Decrease in Inventories	(1,902,050)	(1,860,958)
(Increase)/Decrease in Transit	(143,829)	(1,540,758)
(Increase)/Decrease in Trade Receivable	(70,274,459)	(59,545,256)
(Increase)/Decrease in Deferred Tax Assets	-	3,742,186
(Increase)/Decrease in Advance Deposit & Pre-Payments	(8,705,978)	(5,563,447)
Increase/(Decrease) in Accounts Payable	695,445	(420,560)
Increase/(Decrease) in Liabilities for Expenses	156,816	3,860,095
Increase/(Decrease) in Provision for income tax	5,897,504	9,680,172
Increase/(Decrease) in Deferred Tax Liabilities	1,085,353	(893,657)
	(26,323,262)	(8,401,604)

32.00 Information as per Companies Act, 1994

32.01 Attendance Status of Board Meeting of Directors

During the year, 9 Board Meetings were held. The attendance status of the meetings are as follows:

Name of Directors	Position	Meeting Held	Total Fee
Billal Hossain	Chairman	9	18,000
Mohammad Zakir Hossain Patowary	Managing Director	9	18,000
Md. Kamrul Alam	Director	9	18,000

32.02 Related Party Transaction

(a) Short-term employee benefits:

Name	Designation	Monthly Remuneration	Remuneration	Board Meeting Fee
Billal Hossain	Chairman	100,000	1,200,000	18,000
Mohammad Zakir Hossain Patowary	Managing Director	150,000	1,800,000	18,000
Kamrul Alam	Director	75,000	900,000	18,000
Total			3,900,000	54,000

(b) post-employment benefits	Nil
(c) other long-term benefits	Nil
(d) termination benefits	Nil
(e) share-based payment benefits	Nil

32.03 Payments to Director by the company during the year:

Particulars	30-Jun-23
A. Managerial remuneration paid or payable during the year to the directors, a managing agent or manager.	3,900,000
B. Expenses reimbursed to the managing agent.	
C. Commission or other remuneration payable separately to managing agent or his associate.	
D. Commission or other remuneration payable separately to managing agent or his associate as selling or buying agent of other concerns in respect of contracts entered into by such concerns with the company.	
E. The money value of the contracts for the sale or purchase of goods and materials or supply of services, entered into by the managing agent or his associate during the financial year.	
F. Any other perquisites or benefits in cash or in kind.	
G. Other allowances and commission including guarantee commission.	
H. Pensions etc.	

32.04 Employee position of Al Madina Pharmaceutical Limited as per requirement of schedule XI, part II, Para-3

As of June 30, 2023, the company had a staff of 683 members, in contrast to 674 individuals on June 30, 2022. It's worth mentioning that every employee received an annual total salary surpassing Tk. 36,000.

33.00 Event after Reporting Period

Proposed Dividend Allocation: Board Recommendation and Upcoming Shareholders' Approval

During their meeting on October 09, 2023, the Board of Directors has put forth a recommendation for the allocation of dividends based on retained earning excluding revaluation reserves. The proposal consists of a cash dividend (Excluding directors or sponsors) was 10% per share. The total proposed cash dividend was BDT 61,50,000. These recommendations pertain to the fiscal year that concluded on June 30, 2023.

It's important to note that the financial statements for the year ended June 30, 2023, have not yet incorporated the effects of the aforementioned cash and stock dividends. These effects will be recognized in the accounting period when the shareholders' right to receive the dividend payment is officially established.

Other Events

As of the statement of financial position date, no significant events have been identified that necessitate adjustment or disclosure in these financial statements.

Al-Madina Pharmaceuticals Ltd
Property, Plant and Equipment's Schedule
As at 30 June 2023

SL No	Particulars	Cost			Disposal/Depreciation				Written Down Value As at 30 June, 2023		
		As at 1st Jul-22	Addition	Disposal	As at 30 June, 2023	Rate	As at 1st Jul-22	For the Year		Disposal	As at 30 June, 2023
1	Land and land development	157,082,103	-	-	157,082,103	-	-	-	-	-	157,082,103
2	Factory building and Construction	60,780,248	-	-	60,780,248	5.0%	13,902,460	2,343,889	-	16,246,348	44,533,900
3	Plant and Machinery	167,354,378	1,785,385	-	169,139,763	15.0%	57,075,054	16,987,772	-	74,062,826	95,076,937
4	Generator	662,548	-	-	662,548	15.0%	601,036	9,227	-	610,263	52,285
5	Air conditioner	1,391,713	-	-	1,391,713	15.0%	1,262,503	19,382	-	1,281,885	109,829
6	Water pump	46,459	-	-	46,459	15.0%	41,834	694	-	42,528	3,931
7	Gas line cost	1,136,507	-	-	1,136,507	15.0%	1,030,991	15,827	-	1,046,818	89,689
8	Furniture & fixture	2,472,881	139,700	-	2,612,581	20.0%	998,593	333,107	-	1,331,700	1,280,881
9	Office decoration/Equipment	651,131	730,430	-	1,381,561	15.0%	489,586	185,226	-	674,812	706,749
10	Television	9,835	-	-	9,835	15.0%	8,922	137	-	9,059	776
11	Fridge	22,257	-	-	22,257	15.0%	20,191	310	-	20,501	1,756
12	Electric fittings	1,401,722	35,300	-	1,437,022	15.0%	1,218,562	36,485	-	1,255,047	181,975
13	Motor cycle	1,023,500	-	-	1,023,500	15.0%	918,316	15,778	-	934,094	89,406
14	Computer	1,278,710	-	-	1,278,710	20.0%	439,202	167,902	-	607,104	671,606
15	Computer printer	13,000	-	-	13,000	15.0%	11,664	200	-	11,864	1,136
16	Photocopy machine	61,750	-	-	61,750	10.0%	47,624	1,413	-	49,037	12,713
	Total	395,388,742	2,690,815	-	398,079,557		78,066,537	20,117,348	-	98,183,885	299,895,672
17	Right-of-use - Covered Van	13,328,000	-	-	13,328,000	10.0%	3,227,841	1,010,016	-	4,237,857	9,090,143
18	Right-of-use - Motor Bike	7,422,242	-	-	7,422,242	10.0%	1,678,224	574,402	-	2,252,626	5,169,616
	As on 30 June 2023	416,138,984	2,690,815	-	418,829,799		82,972,602	21,701,766	-	104,674,368	314,155,431
	As on 30 June 2022	386,600,032	29,538,952	-	416,138,984		58,570,562	24,402,039	-	82,972,602	333,166,382

	30 June 2022	30 June 2022 (rearranged)	30 June 2022
Depreciation Charged to:			
Factory Overhead	19,567,368	21,928,309	19,521,631
Administrative & General Expenses	471,412	427,960	4,880,408
Marketing, Selling & Distribution Expenses	1,662,986	2,045,770	-
Total Taka:	21,701,766	24,402,039	24,402,039

During the year, the comparative information as of June 30, 2022, has been reorganized in terms of their utilization of Property, Plant, and Equipment.



AI-Madina Pharmaceuticals Limited

178-179, Two Star Tower (5th Floor), East Tejturi Bazar, Farmgate, Dhaka-1215

PROXY FORM

I/We.....

of.....

.....being a shareholder of AI-Madina Pharmaceuticals Limited, do hereby

appoint Mr./Ms.....of.....

.....

as my/our proxy to attend and vote on my/our behalf at the **17th Annual General Meeting (AGM)** of the Company to be

held on **on Thursday, December 14, 2023 at 11:30 am** through digital platform and can be accessible on the following

link <https://almadinapharma.bdvirtualagm.com>

As witness my/our hand this Day of2023

.....
Signature of Shareholder

Revenue
Stamp of
Tk. 100/-

No. of Shares held:

.....
Signature of proxy

BO ID No.

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

Note:


1. A shareholder entitled to attend and vote in the AGM may appoint a Proxy to attend and vote on his/her behalf.
2. The Proxy Form, duly filed and stamped must be deposited at the Registered Office of the Company or sent through email at anwar.cs.ampl@gmail.com at least 48 hours before the time fixed for the meeting.
3. Signature of the Shareholder(s) must be in accordance with the Specimen Signature recorded with the Company.

.....
(Authorized Signature)

AI-Madina Pharmaceuticals Limited



Al-Madina Pharmaceuticals Ltd.

 178-179, Two Star Tower (5th Floor), East Tejturi Bazar, Farmgate, Dhaka-1215

 info@almadinapharma.com

 +88 02-222245141, +88 02-222245148

www.almadinapharma.com